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Abstract 
All-trans retinoic acid (ATRA) is successful in treating acute promyelocytic leukemia but has 
shown limited success with other cancers. Identifying signaling pathways that confer ATRA 
responsiveness and compounds that enhance the effects of the drug could expand its therapeutic 
efficacy. The leukocyte antigen CD38 is an ectoenzyme and receptor that propels MAPK 
signaling and ATRA-induced differentiation when overexpressed. CD38 enzymatic activity 
regulates calcium flux and NAD metabolism while its receptor functions drive phosphorylation 
of ERK, c-Cbl, and p85 PI3K. We found that crippling enzymatic activity with inhibitors or a 
point mutation (CD38 E226Q) did not affect ATRA induction, while a cytosolic truncation 
(CD38 Δ11-20) that prevented CD38 membrane expression crippled ATRA-induced 
differentiation. This indicated that CD38 receptor function is important for ATRA induction. In 
contrast, we found CD38 Δ11-20 cells responded to the monocytic inducer 1,25-
dihydroxyvitamin D3 similar to wild-type cells, suggesting CD38 signaling is important for 
granulocytic but not monocytic maturation. We also found that CD38 may sustain ERK 
phosphorylation to maintain a cellular precommitment memory associated with ATRA exposure. 
Since CD38 receptor functions appeared necessary for ATRA induction we identified CD38 
interaction partners. These included SLP-76, Vav1, and Lyn, and we found that this complex was 
interrupted by inhibiting Lyn. Lyn inhibition also blocked ATRA- and CD38-stimulated 
phosphorylation of c-Cbl and p85 PI3K, suggesting some aspects of CD38 signaling are 
dependent on Lyn kinase activity. Finally we found that the Lyn inhibitors PP2 and dasatinib 
enhanced ATRA-induced differentiation. Co-treatment with ATRA plus either inhibitor 
upregulated total Lyn and c-RafpS259, and increased associations between Lyn/c-Raf and c-
Raf/ERK. This was consistent with increased c-Raf C-terminus phosphorylation that may be 
regulated by ERK-propelled feedback signaling within a KSR1 scaffold. PP2 and dasatinib had 
different effects on Lyn activity suggesting that Lyn acts as an adaptor/scaffold independent of 
its kinase function. These results provide valuable insight as to how ATRA-regulated molecules 
including CD38, Vav1, SLP-76, Lyn, and the Raf/MEK/ERK axis may enhance the 
differentiation of acute myelogenous leukemia cells. This report also identifies new therapeutic 
targets and compounds that may be used in combination with ATRA to improve its clinical 
efficacy. 
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CHAPTER I: INTRODUCTION 
1.1 All-trans retinoic acid in the treatment of leukemia 
All-trans retinoic acid (ATRA) has proven highly effective in treating patients with acute 
promyelocytic leukemia (APL) which bears the characteristic t(15,17) chromosomal 
translocation. However, the therapeutic use of ATRA has significant limitations [1-5]. First, 
leukemias that are t(15,17) negative typically do not respond well to ATRA treatment, and 
retinoic acid has shown restricted efficacy in treating other types of cancers. Therefore the 
success of ATRA as a therapeutic option has been fairly limited. In addition, some patients 
develop resistance to ATRA or experience post-treatment relapse (which may also be 
characterized by resistance). Therefore it is important to identify cell signaling pathways that 
confer ATRA responsiveness to understand the mechanisms of its therapeutic value. This may 
assist in the identification of molecules and signaling cascades that could constitute new 
therapeutic targets, leading to the improvement of ATRA’s efficacy and broadening its 
usefulness in other types of cancers. It is also of significant interest to identify new compounds 
that can be used in combination with ATRA to improve clinical outcomes. For example, the 
discovery of molecules that, in combination with ATRA, accelerate cell cycle arrest and 
differentiation could be particularly useful in treating patients who have relapsed or developed 
resistance.  
1.2 The t(15,17) negative HL-60 human acute myeloblastic leukemia cell line is a model to 
study ATRA responsiveness 
Bipotent human acute myelogenous leukemia (AML) HL-60 cells do not bear the t(15,17) 
translocation, yet they are still ATRA-responsive. It is a model cell line for studying induced 
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differentiation, since treatment with either ATRA or 1,25-dihydroxyvitamin D3 (D3) results in 
granulocytic or monocytic maturation, respectively. Treatment of HL-60 cells with retinoic acid 
leads to terminal differentiation evidenced by the upregulated expression of classical 
differentiation markers including CD38 and CD11b, inducible oxidative metabolism, and G1/0 
cell cycle arrest. The mechanisms by which ATRA drives t(15,17) negative HL-60 cells to 
differentiate remain unclear. Since ATRA has shown little clinical efficacy in AML treatment, it 
is important to identify the proteins and signaling cascades that confer ATRA responsiveness to 
non-APL HL-60 cells. The investigation of molecular targets and drugs that modulate or enhance 
ATRA induction may have a significant impact on the therapeutic potential of retinoic acid in 
other types of cancers.  
1.3 The role of the leukocyte antigen CD38 in leukemia is enigmatic  
The leukocyte antigen CD38 is a 45kD type II transmembrane receptor and ectoenzyme that is 
differentially expressed in a variety of cells. It has been negatively and positively implicated in 
the prognosis of several diseases, including chronic lymphocytic leukemia (CLL), acquired 
immune deficiency syndrome (AIDS), and diabetes (reviewed in [6]). CD38 is an early 
biomarker of ATRA-induced differentiation in the HL-60 cell line yet its role in this process is 
unclear. CD38 contains a retinoic acid response element (RARE) in the first intron and 
transcription is regulated by retinoic acid receptor-α (RAR-) [7, 8]. The antigen is detectable 
after 6 hours of treatment and reaches maximum expression within 16 hours [9]. A stable 
transfectant cell line that overexpresses wild-type CD38 shows an enhanced rate of 
differentiation indicated by increased inducible oxidative metabolism by 48 hours and G1/0 
arrest by 72 hours [9]. CD38 overexpression and agonist interaction also drives MAPK signaling 
through the c-Raf/MEK/ERK axis, which is required for induced differentiation [10-15]. In 
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addition, RNAi directed toward CD38 cripples ATRA induction [16]. These reports suggest that 
ATRA-induced myeloid differentiation in HL-60 cells may depend in part on the early 
expression of CD38 and the signaling cascades it regulates. Other studies support a role for 
CD38 in white blood cell differentiation and growth suppression, particularly B lymphocytes 
[17-19]. 
In contrast, CD38 is considered a negative prognostic indicator for CLL and may promote 
survival and proliferation through ERK1/2 signaling [20]. Additional reports show that CD38 
ligand-induced signaling results in the proliferation of myeloid leukemia patient cells and cell 
lines [21, 22] or that agonist ligation prevents apoptosis [23]. Also, CD38 expression in HeLa 
cells shortens their doubling time [24]. Therefore the role of CD38 in leukemia remains 
enigmatic. The diverse cellular outcomes modulated by the antigen may reflect the function of 
different domains in different contexts. Identification of the domains that regulate ATRA 
induction would be important in elucidating how CD38 functions in a differentiating leukemia 
cell. 
1.4 Receptor and enzymatic functions of CD38 
CD38 has both enzymatic and receptor functions (Figure 1.1). As an ectoenzyme, it catalyzes the 
formation of adenosine diphosphate ribose (ADPR), cyclic ADPR (cADPR), and nicotinamide 
(NAM) from nicotinamide adenine dinucleotide (NAD+) under neutral pH; or nicotinic acid 
adenine dinucleotide phosphate (NAADP+) from nicotinic adenine dinucleotide phosphate 
(NADP) under acidic conditions [25]. The E226 residue of CD38 is considered essential for 
catalytic activity, since mutagenesis of this site results in a loss of enzymatic function [26-28]. 
Both cADPR and NAADP+ facilitate calcium signaling. CD38 cADPR catalysis mediates  
 4 
 
 
 
 
 
Figure 1.1 Enzymatic and receptor functions of CD38. CD38 extracellular enzymatic activity 
(blue) metabolizes NAD+ to ADPR, cADPR, and NAM, and NAAPD+ to NADP. cADPR and 
NADP are second messengers that modulate calcium flux. Receptor functions (red) are regulated 
by extracellular stimulus from ligands, other membrane proteins, or CD38 
dimer/oligomerization. In HL-60 and NB4 cells, CD38 signaling transduction results in 
phosphorylation of c-Cbl, p-85 PI3K, and ERK. CD38 also regulates a variety of signaling 
mechanisms in other hematopoietic cells, including cytokine secretion.  
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calcium mobilization from the endoplasmic reticulum in astrocytes, cardiomyocytes, and airway 
smooth muscle cells, and is important for chemotactic responses in neutrophils [29-31].  
The role of CD38 enzymatic activity in the context of ATRA-induced differentiation is not 
understood. ATRA-treated HL-60 cells release nuclear calcium in response to cADPR 
production which correlates with the presence of nuclear CD38 protein, suggesting a role in 
differentiation [32]. Another report shows that the CD38/cADPR/Ca
2+
 signaling axis promotes 
proliferation and delays differentiation in PC12 cells [33]. ATRA treatment causes a decrease in 
total cellular calcium levels, and experiments inhibiting calcium flux also suggest independence 
[34, 35]. Investigation of CD38 enzymatic activity after ATRA treatment would elucidate if this 
function is necessary for differentiation.  
CD38 also has receptor functions that participate in diverse signaling mechanisms that vary with 
cell type and differentiation status [36]. Membrane-expressed CD38 forms lateral associations 
with a variety of surface receptors to facilitate signaling. These include CD3 on T lymphocytes; 
surface Ig, CD19, and CD21 on B cells; and CD16 on NK cells [37-39]. These lateral 
membrane-localized interactions result in cytosolic protein complex assembly, which include 
CD38 association with PI3K and Lyn [40, 41]. CD38 m(Ab) agonist ligation (which can 
facilitate dimerization) results in the phosphorylation of c-Cbl and ERK and may also coordinate 
protein complex assembly [13-15, 19, 42]. Therefore, the receptor functions of CD38 can depend 
on interaction with itself and a variety of membrane- or cytosol-localized proteins. 
The receptor functions of CD38 may be independent of enzymatic activity. For example, CD38-
mediated signaling is dependent on conformational changes of the ectodomain that result in 
downstream tyrosine kinase activity, and these functions are enzyme-independent [43, 44]. Since 
 6 
 
CD38 enzymatic function and receptor signaling can drive diverse cellular outcomes, and since 
these two functions can operate independently, there is interest in discovering which molecules 
participate in the regulation of CD38-facilitated signaling cascades. Identification of such 
proteins could provide insight regarding how CD38 propels myeloid differentiation, and 
distinguish additional proteins and effectors that could be key regulators of signaling pathways 
required for ATRA induction. 
1.5 Known and potential CD38-associated molecules including c-Cbl, p85 PI3K, Vav1, and 
SLP-76 regulate signaling and differentiation 
Proteins that show association or potential interaction with CD38, or that are involved in CD38-
stimulated signaling, also show ATRA-related regulatory roles. One such protein is the E3 
ubiquitin ligase and adaptor c-Cbl which, like CD38, promotes MAPK signaling and ATRA-
induced differentiation when overexpressed [42, 45, 46]. CD38 and c-Cbl exist in a complex, and 
a c-Cbl tyrosine kinase binding (TKB) domain mutant (G306E) that does not bind CD38 also 
fails to drive MAPK signaling and differentiation [45]. This suggests that CD38-driven c-Cbl 
phosphorylation and/or its interaction with CD38 could cooperatively propel myeloid 
differentiation by forming critical signaling complexes at the cell membrane. IRF-1 also binds c-
Cbl and drives ATRA induction, as well as MAPK signaling and CD38 expression [48] 
indicating another potential CD38 partner involved in propelling the effects of ATRA. 
c-Cbl is also known to interact with Vav1, SLP-76, and the p85 regulatory subunit of PI3K, 
which suggests these proteins also interact with CD38 [45, 46, 49, 50]. c-Cbl, SLP-76, and Vav1 
protein expression and p85 PI3K activity are upregulated during myeloid differentiation, 
suggesting they have a functional role [51-55].  These proteins also form complexes in myeloid 
cells during ATRA induction which may participate in CD38-coordinated signaling events.  
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For example, CD38 stimulation by the agonists IB4 and T16 induces phosphorylation of the p85 
regulatory subunit of PI3K and its association with c-Cbl, which is correlated with normal and 
leukemic B cell growth suppression [19, 56]. Consistent with this, PI3K inhibitors relieve CD38-
mediated growth suppression [19]. This suggests a negative regulatory role for a CD38/PI3K/c-
Cbl complex in cell growth. Accordingly c-Cbl is reported to be a negative regulator of PI3K 
either through its E3 ubiquitin ligase activity [57, 58] or through sequestration. For example, c-
Cbl phosphorylation at Y731 by a Src family kinase (SFKs) creates a docking site for the p85 
subunit of PI3K which can negatively regulate survival [49, 59, 60]. Likewise Cbl-b promotes 
apoptosis in rat leukemia cells by suppressing PI3K activation while enhancing MEK/ERK 
activation [61]. PI3K could be important for the efficacy of ATRA in other types of cancer, since 
retinoic acid has shown promise in treating reproductive leiomyomas by modulating proteins 
involved in the PI3K cascade [62]. 
c-Cbl interaction with the adaptor protein SLP-76 and the guanine nucleotide exchange factor 
(GEF) Vav1 increases after ATRA treatment in HL-60 cells [45], and therefore Vav1 interacts 
with c-Cbl and SLP-76 in a differentiation-dependent manner. Vav1/c-Cbl complexes appear in 
the cytosol while Vav1/SLP-76 interactions occur in nuclei, suggesting that these complexes 
participate in localized cell signaling after ATRA treatment [63]. SLP-76 interacts with Vav1 
through an SH2 binding domain, where Vav1 may serve as a scaffold to stabilize SLP-76 
signaling microclusters [64, 65]. Co-expression of SLP-76 with CSF-1/c-FMS enhances ATRA-
induced ERK activation, the expression of the differentiation maker paxillin, inducible oxidative 
metabolism, RA-induced RB tumor suppressor protein hypophosphorylation, and G1/0 cell cycle 
arrest [53].  Therefore, SLP-76 interaction with proteins such as c-Cbl, c-FMS, Vav1, and 
potentially CD38 may regulate aspects of ATRA induction including ERK signaling. 
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Like c-Cbl, tyrosine-phosphorylated Vav1 associates with PI3K and may facilitate the 
characteristic nucleoskeleton remodeling that occurs after ATRA treatment in HL-60 cells, 
which is independent of its activity as a GEF [63, 66]. Consistent with this, downmodulation of 
Vav1 in ATRA-treated HL-60 and NB4 cells impedes myeloid differentiation, nucleoskeleton 
remodeling, and affects differentiation-related protein expression [55].  
Phosphorylation of Vav1 at Y745 is believed to play a critical role in ATRA-induced maturation 
of leukemic NB4 cells since mutation of this residue interferes with retinoic acid-propelled 
CD11b α-integrin receptor expression and cell migration [67]. Vav1 regulates the ATRA-
induced expression of CD11b by recruitment to its promoter with the PU.1 transcription factor 
[68]. Consistent with this, Vav1-targeted siRNA resulted in significantly decreased ATRA-
induced CD11b and modulated the expression of proteins that are associated with cell cycle, 
apoptosis, and cytoskeleton organization [55]. Overexpression of CD38 also enhances CD11b 
suggesting cooperation with Vav1.  
Finally, CD38 drives transient MAPK signaling after agonist ligation [13-15]. In contrast, wild-
type CD38 overexpression in a stable transfectant cell line creates a persistent p-ERK signal [9]. 
Transient or protracted signaling from this cascade can lead to either cell proliferation or 
differentiation respectively [69], and sustained MAPK signaling is required for ATRA-induced 
differentiation since inhibitors of c-Raf and MEK interrupt this process [10, 12]. Therefore, 
CD38 could differentially regulate MAPK signaling and perturb the magnitude and duration of 
the signal. This could explain the ambiguity of CD38 as a receptor that drives proliferation or 
growth suppression, and supports its ability to regulate diverse cellular outcomes through signal 
switching. For example ATRA-induced PI3K signaling, which may be regulated by CD38, can 
be biphasic evidenced by an initial increase in p-Akt followed by decreased Akt phosphorylation. 
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In this case PI3K cooperates with MAPK regulators to propel differentiation [52, 70, 71]. Since 
CD38 also appears capable of signal switching it could regulate the biphasic responses of 
effectors including PI3K and MAPK cascades. 
c-Raf regulation and its post-translational modification are of particular interest in MAPK 
signaling induced by ATRA and driven by CD38. Expression of activated c-Raf drives ATRA-
induced differentiation [72] and supports its role in propelling persistent MAPK signaling 
required for ATRA induction. In addition, c-Raf phosphorylated at S621 migrates to the nucleus 
and is associated with differentiation [73]. Finally c-Raf may be involved in feedback signaling 
that fine-tunes the character of MAPK signaling propelled by ATRA. For example, ERK can 
directly mediate feedback phosphorylation of c-Raf on residues S287, S296, and S301, which 
controls Raf activation and attenuates mitogenic signaling [74, 75]. 
1.6 ATRA-induced SFKs including Lyn participate in CD38-driven signaling and associate 
with CD38 accessory molecules 
SFKs are a unique group of enzymes that have diverse roles in cell proliferation, survival, 
differentiation, adhesion, and migration. These proteins regulate hematopoiesis and can also 
contribute to hematopoietic cancers. One historically prominent paradigm of Src action is 
positive regulation of MAPK signaling and cell proliferation that contributes to cell 
transformation (reviewed in [76]). Yet a persistent MAPK signal characterizes ATRA-induced 
differentiation, thus SFKs may positively regulate ATRA induction. In support of this, SFKs are 
known to be upregulated after ATRA treatment [77, 78]. 
Lyn is an SFK of particular interest due to its contrasting roles in hematopoietic cell proliferation 
and differentiation. On one hand, Lyn is considered a negative regulator of hematopoiesis. A 
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gain-of-function Y527F mutation did not result in murine hematopoietic malignancy, but Lyn -/- 
mice showed myeloid progenitor proliferation and tumors [79]. This and other studies also report 
that Lyn is required for ITIM-dependent inhibitory signaling and phosphatase activity, loss of 
which may lead to tumorigenesis [80]. Lyn is an important regulator of the G-CSF receptor and 
negatively modulates G-CSF-stimulated granulpoiesis and growth of myeloid and multipotential 
progenitors in the bone marrow, and proliferation in other hematopoietic cells [81-83].  
SFKs including Lyn also interact with CD38-associated molecules. As previously noted, SFKs 
can phosphorylate c-Cbl to create a docking site for the p85 subunit of PI3K [49]. SFKs may also 
directly phosphorylate p85 PI3K [84]. In this report the authors suggest that c-Cbl may act as a 
scaffold between Src and PI3K. Lyn has specifically been linked to CD38-stimulated signaling 
events that result in both proliferation and differentiation. For example, CD38 stimulation of B 
lymphocytes obtained from Lyn-deficient mice showed defective maturation, and drugs 
interfering with PI3K or ERK also decreased CD38-driven differentiation [17]. This suggests 
that Lyn may cooperate with other CD38-associated signaling molecules, such as PI3K and 
ERK. Other reports show that both Fyn and Lyn are required for B cell signaling after CD38 
ligation [85]. Likewise, in lymphoblastoid B cell membrane rafts, CD38 is associated with Lyn 
and promotes cell signaling [41]. 
1.7 SFK/Lyn expression and activity may regulate leukemia cell differentiation  
Reports that SFKs, particularly Lyn, can interact with CD38 and potentially modulate its 
receptor function motivates interest in the role of SFK/Lyn expression and activity during 
ATRA-induced differentiation, and if SFK inhibitors can enhance the effects of ATRA. For 
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example, Lyn is the predominant active SFK expressed in AML cells [86, 87], and blocking 
activity has been effective in slowing leukemic cell growth [88].  
Several reports provide fragmentary data indicating that SFK activity and expression could also 
modulate ATRA differentiation induction therapy. Miranda et al. recently reported that the 
inhibitor PP2 potentiated ATRA-induced gene expression and enhanced the differentiation 
marker CD11b in myeloid NB4, HL-60, and primary APL cells [89]. Kropf et al. recently 
reported that dasatinib also increased ATRA-induced CD11b expression [87]. Other studies 
show that Lyn and Fgr are upregulated in HL-60 and NB4 myeloid leukemia cells after ATRA 
treatment and prevent apoptosis during granulocytic differentiation [78, 90].    
SFK inhibitors are capable of both positive and negative regulatory effects on MAPK pathway 
components, supporting the notion that they may regulate ATRA induction. PP2 enhances Ras-
independent Raf-1 activation that is mediated by Raf S621 phosphorylation [91], suggesting that 
SFK inhibitors are able to positively regulate Raf. This implies that SFKs could modulate c-Raf 
phosphorylation status and its ability to orchestrate MAPK feedback signaling. In contrast, the 
inhibitor dasatinib blocks MAPK activity in the absence of growth factors (GFs) and attenuates 
signaling in the presence of GFs in CML progenitors [92]. MAPK signal perturbation by SFKs 
may have implications for ATRA induction therapy, since retinoic acid results in sustained 
MAPK signaling which is required for HL-60 maturation [10, 12, 46].  
The ability of SFKs to potentially regulate ATRA-induced differentiation and MAPK signaling 
is thus not understood. This motivates interest in how SFK inhibitors can affect the extent of 
ATRA-induced phenotypic conversion and if MAPK regulatory molecules are involved.  
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1.8 Project Overview 
The data described above motivated several principal research questions. First, it would be 
important to elucidate which domains of CD38 drive differentiation. Therefore we investigated 
whether its functions as a receptor, ectoenzyme, or both were important for ATRA induction. 
Second, the identification of proteins that partner with CD38 to drive signaling, and how they 
may regulate such activity, is integral to understanding how CD38 modulates differentiation and 
may point to new therapeutic targets. This led to an analysis of which proteins complexed with 
CD38 and how these interactions were affected by CD38 stimulation, ATRA induction, or CD38 
expression in the absence of ATRA. Finally, we investigated whether compounds or drugs that 
impinge on CD38-associated molecules are able to enhance the efficacy of ATRA.  Ultimately, 
these results could have substantial implications for the use of ATRA in a wider variety of 
leukemia types, and provide co-treatment options for patients that have developed resistance or 
relapsed. The results discussed in this dissertation address these research questions and provide 
information that could significantly impact the clinical use of ATRA. 
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CHAPTER II 
ATRA-INDUCED HL-60 MYELOID LEUKEMIA CELL DIFFERENTIATION 
DEPENDS ON THE CD38 CYTOSOLIC TAIL NEEDED FOR MEMBRANE 
LOCALIZATION, BUT CD38 ENZYMATIC ACTIVITY IS UNNECESSARY 
 
2.1 Abstract 
Leukocyte antigen CD38 expression is an early marker of all-trans retinoic acid (ATRA) 
stimulated differentiation in the leukemic cell line HL-60. It promotes induced myeloid 
maturation when overexpressed, whereas knocking it down is inhibitory. It is a type II membrane 
protein with an extracellular C-terminal enzymatic domain with NADase/NADPase and ADPR 
cyclase activity and a short cytoplasmic N-terminal tail. Here we determined whether CD38 
enzymatic activity or the cytoplasmic tail is required for ATRA-induced differentiation. Neither 
a specific CD38 ectoenzyme inhibitor nor a point mutation that cripples enzymatic activity 
(CD38 E226Q) diminishes ATRA-induced differentiation or G1/0 arrest. In contrast a cytosolic 
deletion mutation (CD38 Δ11-20) prevents membrane expression and inhibits differentiation and 
G1/0 arrest. These results may be consistent with disrupting the function of critical molecules 
necessary for membrane-expressed CD38 signal transduction. One candidate molecule is the Src 
family kinase Fgr, which failed to undergo ATRA-induced upregulation in CD38 Δ11-20 
expressing cells. Another is Vav1, which also showed only basal expression after ATRA 
treatment in CD38 Δ11-20 expressing cells. Therefore, the ability of CD38 to propel ATRA-
induced myeloid differentiation and G1/0 arrest is unimpaired by loss of its ectoenzyme activity. 
However a cytosolic tail deletion mutation disrupted membrane localization and inhibited 
differentiation. ATRA-induced differentiation thus does not require the CD38 ectoenzyme 
function, but is dependent on a membrane receptor function.  
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2.2 Introduction 
All-trans retinoic acid (ATRA) leads to the myeloid differentiation and G1/0 arrest of HL-60 
human myeloblastic leukemia cells. The process may depend on the early ATRA-induced 
expression of the leukocyte antigen CD38, a 45kD type II transmembrane glycoprotein that has 
both enzymatic and receptor functions. It is an early biomarker of ATRA-induced differentiation 
in the HL-60 cell line that is detectable after 6 hours of treatment and reaches maximum 
expression within 16 hours [1]. CD38 may play a causal role in HL-60 myeloid differentiation, 
since RNAi directed toward CD38 crippled ATRA induction [2]. Transfectants that overexpress 
wild-type CD38 show an enhanced rate of differentiation indicated by increased inducible 
oxidative metabolism by 48 hours and G1/0 arrest by 72 hours [1].  
CD38 is an ectoenzyme that catalyzes the formation of adenosine diphosphate ribose (ADPR), 
cyclic ADPR (cADPR), and nicotinamide from NAD+ under neutral pH; or NAADP+ from 
NADP under acidic conditions [3]. Both cADPR and NAADP+ facilitate calcium signaling. 
ATRA-treated HL-60 cells release nuclear calcium in response to cADPR production that 
correlates with the presence of nuclear CD38 protein, suggesting a role in differentiation [4]. 
However, ATRA-induced differentiation causes a decrease in total cellular calcium levels, and 
studies of calcium flux inhibition during ATRA treatment also suggested independence [5, 6]. 
Thus the precise role of calcium flux and its stimulation is not fully understood.  
In addition to its enzymatic activity, CD38 has receptor functions that participate in diverse 
signaling mechanisms that vary with cell type and differentiation status [7]. Membrane-
expressed CD38 forms lateral associations with CD3 on T lymphocytes; with surface Ig, CD19, 
and CD21 on B cells; and with CD16 on NK cells to produce signaling events [8-10]. In human 
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B cell precursors, ligation results in tyrosine phosphorylation of proteins such as Syk, 
phospholipase C-, and the p85 subunit of PI3K [11]. In myeloid cells, CD38 m(Ab)-induced 
tyrosine phosphorylation can be mediated through FcγII receptors [12]. In HL-60 cells CD38-
agonist interaction also results in phosphorylation of c-Cbl, a cytosolic adapter molecule known 
to promote MAPK signaling and ATRA-induced differentiation [13, 14]. Fluorescence resonance 
energy transfer (FRET) data and immunoprecipitation experiments show that these proteins exist 
in a complex [15].  
CD38 also drives MAPK activation after agonist ligation, which is orchestrated by Raf, MEK, 
and ERK [16, 17]. Transient or protracted signaling from this cascade can lead to either cell 
proliferation or differentiation respectively [18], and sustained MAPK signaling is required for 
ATRA-induced differentiation [19, 20].  
In myeloid cells, CD38 signaling may promote either cell proliferation or growth inhibitory 
signals [21, 22]. The apparently divergent functions, particularly within myeloid cell lines, make 
the role of CD38 somewhat enigmatic. It may reflect the function of different domains and their 
relative activities in different contexts. Given that the enzymatic activity, receptor signaling, and 
downstream effectors of CD38 might produce divergent outcomes, and that CD38 likely 
participates directly in differentiation, we investigated which domains of CD38 are required for 
ATRA-induced HL-60 myeloid differentiation. Our results showed that the enzymatic activity of 
CD38 is expendable, while the transmembrane proximal cytosolic region needed for membrane 
expression is required.  
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2.3 Materials and Methods 
Cell culture. HL-60 human myeloblastic leukemia cells and stable transfectant cell lines (CD38 
E226Q, WT38, and CD38 Δ11-20) were grown in RPMI 1640 supplemented with 5% heat-
inactivated fetal bovine
 
serum purchased from Invitrogen (Carlsbad, CA) in a 5% CO2 
humidified atmosphere at 37
o
C. All-trans-retinoic acid (ATRA) was purchased from Sigma (St. 
Louis, MO) and solubilized in ethanol. Cells were cultured in a final concentration of 1 µM. 
Arabinosyl 2′-fluoro-2′-deoxy NAD (F-araNAD) small molecules were suspended in water and 
cells were cultured in a final concentration of 5 µM. For some experiments additional 5 µM 
doses were added every 24 hours to compensate for possible inhibitor degradation.  
Antibodies and reagents. F-araNAD was synthesized following published procedures [23]. 
Antibodies for cytometric analysis of CD38 and CD11b, and CD38 Western blot antibody were 
purchased from Invitrogen and BD Pharmingen (San Jose, CA), respectively. Fgr antibody was 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA); HRP anti-mouse, HRP anti-rabbit, 
Vav1, GAPDH, and p-ERK were purchased from Cell Signaling (Danvers, MA); and anti-total 
ERK from Zymed (San Francisco, CA). M-PER Mammalian Protein Extraction Reagent lysis 
buffer was purchased from Pierce (Rockford, IL). Protease and phosphatase inhibitors, 
nicotinamide guanine dinucleotide (NGD+), propidium iodide, dimethyl sulfoxide (DMSO), and 
12-O-Tetradecanoylphorbol 13-acetate (TPA) were purchased from Sigma, and 5-(and-6)-
chloromethyl-2',7'-dichlorodihydrofluorescein diacetate acetyl ester (CM-H2DCFDA) or DCFH 
was purchased from Invitrogen.  
Generation of stable transfectants. WT38 cell lines were created as previously described [1]. 
Stable transfectants were sorted to enrich the population for cells with transfected expression by 
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flow cytometry using anti-CD38. CD38 E226Q was created by transfecting HL-60 cells with a 
pIRES-hr GFP II vector purchased from Stratagene (La Jolla, CA) containing a CD38 PCR 
product flanked by 5’ EcoRV (GATATCATGGCCAACTGCGAGTTCAGCCCGGTG) and 3’ 
NotI restriction sites (GCGGCCGCTCAGATGTGCAAGATGAATCCTCAGGATTTTTCAC). 
Site-directed mutagenesis was used to create the CD38 E226Q point mutation using the 
(GCACTTTTGGGAGTGTGCAAGTCCATAATTTGCAACCAG) sequence. Stable 
transfectants were sorted by flow cytometry based on CD38 immunostaining.  
The CD38 Δ11-20 cell line was created using an identical pIRES-hr GFP II vector with CD38 
cDNA containing a deletion of amino acids 11-20 with a HindIII site bridging nucleotides 30-61. 
The cDNA fragment was cloned into the vector with 5’ EcoRV and 3’ Not1 restriction sites. 
Segment 1: 5’ EcoRV forward (GATATCAGTGAAACAGAAGGGGAGGTGCAGTTTCAG) 
and 3’ HindIII reverse (AAGCTTCCCGGACACCGGGCTGAACTCGCAGTT); Segment 2: 3’ 
HindIII forward (AAGCTTGCCCAACTCTGTCTTGGCGTCAGTATCCTG) and 5’ Not1 
reverse (GCGGCCGCTCAGATGTGCAAGATGAATCCTCAGGATTT). Stable transfectants 
were created by flow cytometric sorting for GFP-positive cells. Stably transfected cell lines 
containing CD38 E226Q mutations and the CD38 Δ11-20 truncation were further verified by 
mRNA isolation followed by reverse transcriptase PCR amplification and gel analysis and 
sequencing. 
mRNA isolation and sequencing. Total RNA was extracted from the CD38 E226Q and CD38 
Δ11-20 cell lines with Invitrogen Trizol reagent per the manufacturer’s protocol. Total RNA was 
measured by a spectrofluorometer (Beckman Coulter, CA), and reverse transcriptase polymerase 
chain reaction (RT-PCR) was performed using Invitrogen SuperScript One-Step RT-PCR with 
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Platinum Taq. The appropriate DNA sequences were then verified by sequencing at Cornell 
University’s Life Sciences Core Laboratory. 
Flow cytometric phenotypic analysis. Immunostaining for CD11b and CD38 was performed as 
previously described using a Becton Dickinson LSR II flow cytometer (San Jose, CA) [15]. 
Gating was set to exclude 95% of the negative control. Respiratory burst capability was 
measured as previously described [6]. Propidium
 
iodide (PI) cell cycle analysis was performed as 
previously described [15]. 
Western blot analysis. For Western blot analysis, cells were pelleted, washed, and lysed with ice 
cold Pierce M-PER Mammalian Protein Extraction Reagent (Rockford, IL) with a protease 
inhibitor cocktail containing 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), pepstatinA, E-
64, bestatin, leupeptin, and aprotinin (Sigma); and a phosphatase inhibitor cocktail containing 
sodium vanadate, sodium molybdate, sodium tartrate, and imidazoleprotease (Sigma). Samples 
were incubated on ice and debris was pelleted. Protein content was determined by Pierce BCA 
protein reagent assay. Lysate was subjected to standard SDS-PAGE. Membranes were then 
probed with antibodies described above. All blot films shown were transferred to the same 
membrane and are the same exposure. 
Detection of CD38 enzymatic activity. ADP-ribosyl cyclase activity was detected by fluorometric 
analysis of the NGD+ metabolic product cyclic GDP-ribose (cGDPR) using a spectrofluorometer 
(Horiba Jobin Yvon Fluoro Max3, NJ) as previously described [24, 25]. For the CD38 F-
araNAD inhibitor assay, cells were cultured for 48 hours untreated or in the presence of 1 μM 
ATRA to induce CD38 expression. Appropriate samples were treated with 5 μM F-araNAD or 
left untreated for 30 minutes with constant rotation at 37
o
C with protease and phosphatase 
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inhibitors. All samples evaluated for CD38 enzymatic activity were treated with 100 μM NGD+ 
for one hour with constant rotation at 37
o
C. Cells were then pelleted, and supernatant was 
subjected to fluorometric analysis for cGDPR. 
Statistics. Statistics were analyzed by JMP Statistical Discovery Software and Microsoft Excel 
statistical software. 
2.4 Results 
2.4.1 CD38 enzymatic inhibitors do not compromise ATRA-induced differentiation or G1/0 
arrest. CD38 enzymatic ADPR cyclase activity is important for calcium mobilization and 
therefore potentially relevant to differentiation. The enzymatic activity and the receptor signaling 
of CD38 are reportedly uncoupled, and ADPR or cADPR generation is thought to be 
independent of signaling mechanisms [26, 27]. Therefore, we investigated whether crippling the 
enzymatic activity of CD38 influenced ATRA-induced differentiation.  
We first tested whether a small molecule inhibitor of CD38 can interfere with ATRA-induced 
HL-60 cell differentiation. Arabinosyl 2′-fluoro-2′-deoxy NAD (F-araNAD) was added with 
ATRA. F-araNAD is a cell impermeable known suicide substrate that inhibits CD38 ectoenzyme 
activity by forming a covalent adduct with E226 in the active pocket [23, 28].  CD38 has the 
potential to be internalized [29-32], including to the nucleus. Since the binding of F-araNAD to 
CD38 is covalent, then the internalized CD38 would be expected to retain the inhibitor. To verify 
the ability of F-araNAD to block CD38 enzymatic activity, we used the fluorometric NGD+ 
substrate assay. NGD+ is a NAD+ analog that can be cyclized by CD38 to cGDPR, a stable 
fluorescent product. We compared the fluorescence of untreated HL-60 cells with and without 
  
27 
 
 
 
 
 
Figure 2.1 CD38 inhibitors do not affect ATRA-induced differentiation markers. A: Cells 
were cultured for 48 hours with or without 1 μM ATRA and cells were assayed for cGDPR 
production by NGD+ assay. The fold increase of cGDPR production was calculated by 
normalizing each sample to an arbitrary null control value of 1 (*p=<0.05). B: Membrane 
CD11b expression was measured by flow cytometry at indicated time points. (*p=<0.05 
significantly higher than HL-60 cells that were not treated with ATRA.) C: HL-60 cells were 
treated or not with 1 μM ATRA for 72 hours. Appropriate samples were incubated with 5 μM F-
araNAD. Cell cycle phase distribution was determined by flow cytometry with propidium iodide 
staining. (*p=<0.05 significantly higher than untreated G1/0 sample groups; #p=<0.05 
significantly lower than untreated S sample groups.) D: Cell density was measured using a 
hemocytometer and 0.2% Trypan blue exclusion staining.  
 
  
  
28 
 
NGD+ substrate and found no significant differences, indicating that untreated control cells had 
negligible ADPR cyclase activity (data not shown). We then compared the relative amount of 
cGDPR fluorescence generated by untreated cells, ATRA-treated HL-60 cells expressing CD38, 
or cells co-treated with ATRA plus 5 μM F-araNAD (Fig. 2.1a). Fluorescence is reported in 
arbitrary units where 1 is the null background of control cells without CD38. While there was a 
significant difference in fluorescence between untreated cells and cells treated with ATRA, there 
were no apparent differences between control cells and co-treated cells. The inhibitor was 
therefore effective in crippling CD38 catalytic activity. 
Next we determined the effects of CD38 inhibitors on ATRA-induced differentiation. ATRA 
treatment causes HL-60 cells to exhibit differentiation markers such as the α-integrin receptor 
subunit CD11b. F-araNAD had no apparent effect on ATRA-induced CD11b expression, with or 
without ATRA treatment (Figure 2.1b). 
ATRA-treated HL-60 cells also undergo G1/0 enrichment, indicating cell cycle arrest. Cells were 
cultured with or without retinoic acid, and with or without 5 μM F-araNAD for 72 hours. The 
proportion of G1/0 cells in neither ATRA-treated samples nor untreated samples was affected by 
inhibitor treatment (Figure 2.1c). Cell density was also measured during 72 hours to detect 
growth arrest (Figure 2.1d). ATRA-treated samples, regardless of F-araNAD treatment, show 
similar growth retardation at 72 hours. Untreated HL-60 cells and cells treated only with the 
inhibitor show continuous exponential growth. Therefore, inhibition of CD38 enzymatic activity 
by F-araNAD did not affect several markers of ATRA-induced myeloid differentiation. A second 
inhibitor, Arabinosyl-2′-fluoro-2′-deoxy nicotinamide mononucleotide (F-araNMN), was also 
tested and similarly failed to affect ATRA-induced differentiation and corroborated these results 
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(data not shown). 
2.4.2 An E226Q mutation does not alter CD38 effects on ATRA-induced differentiation or G1/0 
arrest. The experiments using pharmacological inhibition indicated that inhibiting the 
ectoenzyme activity of the endogenous CD38 did not affect induced differentiation, suggesting 
that the ectoenzyme activity is not critical. This gives rise to an anticipation that was tested. 
Since ectopic expression of wild-type CD38 promotes induced differentiation, then the 
enzymatically inactive [33] CD38 E226Q catalytic mutant would be expected to do the same if 
the ectoenzyme activity was not needed for this. Therefore, we ectopically expressed CD38 
E226Q and investigated whether or not overexpression of CD38 E226Q was able to similarly 
drive ATRA induction. 
We created cells stably transfected with the CD38 E226Q catalytic mutant and verified the 
mutation by sequencing. Expression of protein was confirmed by flow cytometry of 
immunostained cells (Figure 2.2a). Cell viability was unaffected by E226Q expression since cells 
showed normal growth, no increase in Trypan Blue exclusion staining, and no detectable sub-G1 
population using cytometric propidium iodide staining (data not shown). Expression of CD38 
after ATRA treatment was comparable in both WT38 and CD38 E226Q transfectants, allowing 
comparison without caveats due to achieving different expression levels (data not shown). The 
enzymatic activity for CD38 E226Q was tested using the NGD+ assay.  cGDPR levels in E226Q 
cells were comparable to that of untreated HL-60 cells, showing that the point mutation was 
effective in crippling catalytic activity (Figure 2.2b). ATRA-treated HL-60 cells expressing 
CD38 were used as a positive control. 
Cells stably transfected with wild-type CD38 (WT38) showed enhanced ATRA-induced
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Figure 2.2 CD38 E226Q is able to promote ATRA induction similar to wild-type CD38. A: 
Flow cytometry immunostaining for CD38 in untreated HL-60 cells and CD38 E226Q stable 
transfectants. B: Cells were assayed for cGDPR production by NGD+ assay. The fold increase of 
cGDPR production was calculated by normalizing each sample to an arbitrary null control value 
of 1 (*p=<0.05). C: Cells were treated for 24 hours with ATRA, and induced CD11b expression 
was measured by flow cytometry (top left); cells were treated for 48 hours with ATRA, and 
inducible oxidative metabolism was measured by DCF assay (top right; *=p<0.5 significantly 
lower than WT38 and CD38 E226Q); cell lines were cultured with ATRA for 72 hours and cell 
cycle phase distribution was determined by nuclear propidium iodide staining (bottom). No 
significant differences (p=<0.05) were detected between WT38 and CD38 E226Q samples in any 
of the above experiments. 
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differentiation [1]. To determine if CD38 E226Q and WT38 cells propelled differentiation 
similarly, we analyzed several markers to investigate whether or not the catalytic mutation had 
any affect. We first compared CD11b expression in response to ATRA in HL-60, WT38, and 
CD38 E226Q cells. After 24 hours, both WT38 and CD38 E226Q showed increased CD11b 
expression compared to ATRA-treated HL-60 cells (Figure 2.2c, top left). We then compared 
oxidative metabolism capability. After 48 hours ATRA-treated WT38 and CD38 E226Q showed 
a comparable increase in inducible oxidative metabolism, which was significantly higher than 
ATRA-treated HL-60 cells (Figure 2.2c, top right). These results suggested that both WT38 and 
CD38 E226Q expressing cells are similarly capable of enhancing functional differentiation.  
Finally, to determine if there were effects on cell cycle inhibition, we analyzed ATRA-induced 
G1/0 arrest. ATRA-treated HL-60, CD38 E226Q, and WT38 cells all showed similar G1/0 arrest 
by 72 hours (Figure 2.2c, bottom). CD38 E226Q transfected cells thus underwent differentiation 
indistinguishably from WT38 cells in response to ATRA. Like wild-type CD38, CD38 E226Q 
was also able to enhance CD11b expression and inducible oxidative metabolism compared to 
HL-60 cells. This confirms the anticipation of the earlier F-araNAD results.  
2.4.3 A cytosolic deletion prevents membrane expression in CD38 transfectants. The CD38 
cytosolic N-terminal tail is dispensable for signaling in pro-B cells [34, 35]. However, Moreno-
Garcia et al. show that the cytosolic tail is important for CD38 homodimer stabilization and a 
truncation mutant decreases the half-life of membrane expression in murine B lymphocytes [36], 
which may be important for signaling. To assess the contribution of the short CD38 cytosolic tail 
to ATRA induction, we determined whether a deletion affected membrane expression of CD38 
or ATRA-induced HL-60 differentiation. Ten amino acids were truncated in the cytosolic N 
terminus proximal to the transmembrane region (Figure 2.3a). These 10 residues were reported  
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Figure 2.3 A CD38 cytosolic deletion mutant does not express on the membrane. A: CD38 
N-terminal cytosolic and transmembrane amino acids are shown. Deleted amino acids are in bold 
and underlined. Positively charged amino acids are indicated with a +. B: GFP-positive 
population in HL-60 and CD38 Δ11-20 cells. C: mRNA from HL-60 cells and CD38 Δ11-20 
was subjected to reverse-transcriptase PCR for CD38 expression and visualized on an agarose 
gel (top). Western blot for total CD38 protein in CD38 Δ11-20 and HL-60 cells, with and 
without 48 hours of ATRA treatment (bottom). Untreated HL-60 cells were used as a negative 
control for showing CD38 Δ11-20 expression in transfectants. D: Membrane expression of CD38 
was measured after 24 hours of culture by immunostaining and flow cytometry.  
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 to be necessary for interaction with Lck, a Src family kinase, in T cell signaling events [9, 37] 
and were considered good candidates for interactions with other proteins in different cell lines.  
Stable transfectants expressing the CD38 Δ11-20 deletion were isolated by FACS sorting using a 
GFP marker co-expressed from a CD38Δ11-20/GFP bicistronic transcript with an IRES element 
(Figure 2.3b). The deletion was confirmed by mRNA isolation followed by reverse transcriptase 
PCR and gel analysis, and protein expression was confirmed by Western blot (Figure 2.3c). Cell 
viability was unaffected by CD38 Δ11-20 overexpression since cells showed normal growth, no 
increase in Trypan Blue exclusion staining, and no detectable sub-G1 population using 
cytometric propidium iodide staining (data not shown). Interestingly, although ATRA-treated 
HL-60 cells expressing wild-type CD38 were able to be membrane-labeled with antibody, cells 
expressing CD38 Δ11-20 showed minimal labeling and no significant difference in membrane 
expression compared to the untreated control (Figure 2.3d). The lack of CD38 Δ11-20 membrane 
expression could reflect the loss of the positively charged residues in the transmembrane-
proximal cytosolic region, which may be essential for proper membrane insertion and 
orientation. This is consistent with studies that report CD38 mutant proteins with truncated 
cytosolic regions show significantly reduced membrane expression and half-lives compared to 
wild-type protein [36]. After CD38 Δ11-20 transfectants were treated with ATRA, membrane 
expression of CD38 was comparable to that of ATRA-treated HL-60 cells consistent with 
endogenous CD38 expression.  
2.4.4 CD38 Δ11-20 cripples ATRA-induced differentiation induction. To determine the effect of 
the Δ11-20 deletion on ATRA induction, we conducted flow cytometric analyses of HL-60 cells 
and CD38 Δ11-20 transfectants to assess their ability to undergo differentiation. Compared to 
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Figure 2.4 CD38 Δ11-20 expression interrupts differentiation markers. A: Membrane 
CD11b expression was measured by immunostaining and flow cytometry at indicated time 
points. (*p=<0.05 significantly higher than untreated HL-60 cells at the same time point.) B: 
After 72 hours, inducible oxidative metabolism was measured by flow cytometry using the DCF 
assay. (*p=<0.05 significantly higher than untreated HL-60 cells.) C: Cells were cultured for 72 
hours with or without ATRA and cell cycle phase distribution was determined by nuclear 
propidium iodide staining. (*p=<0.05 G1/0 phase was significantly enriched compared to 
untreated HL-60 cells; #=p<0.05 S phase was significantly lower than untreated HL-60 cells.) 
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ATRA-treated HL-60 cells, treated CD38 Δ11-20 transfectants showed significantly less CD11b 
expression at 24 and 48 hours, and decreased expression at 72 hours (Figure 2.4a). This indicated 
that expression of the Δ11-20 deletion decreased ATRA-induced expression of CD11b. 
Next we analyzed inducible oxidative metabolism after ATRA treatment. For HL-60 cells, the 
percentage capable of producing reactive oxygen species (ROS) increased to approximately 70% 
at 72 hours compared to the untreated control (Figure 2.4b). However, CD38 Δ11-20 
transfectants showed a lack of oxidative metabolism capability, indicating CD38 Δ11-20 
transfectants are unable to undergo the inducible respiratory burst characteristic of mature 
myeloid cells. 
After 72 hours of ATRA treatment, HL-60 cells showed significant G1/0 DNA enrichment 
compared to the untreated counterparts (Figure 2.4c). However, after ATRA treatment the 
percentage of CD38 Δ11-20 cells in G1/0 was not significantly different than untreated HL-60 
cells, indicative of crippled ATRA-induced G1/0 arrest. Together, these results indicate that 
CD38 Δ11-20 is able to inhibit terminal differentiation as evidenced by crippled G1/0 
enrichment and oxidative metabolism, and decreased expression of CD11b. 
2.4.5 CD38 Δ11-20 expression affects signaling proteins regulated by ATRA. MAPK signaling 
can result in cell proliferation or arrest and differentiation, depending on receptor type and 
signaling longevity [18, 38]. During ATRA-induced HL-60 differentiation, a protracted 
Raf/MEK/ERK signal is required, and inhibitors of Raf and MEK block HL-60 leukemic cell 
maturation [19, 20]. Overexpression of wild-type CD38 drives MAPK signaling on its own and 
results in sustained, upregulated ERK signaling without ATRA treatment [1]. This motivated 
interest in whether the CD38 Δ11-20 mutant is capable of driving MAPK signaling. 
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Figure 2.5 CD38 Δ11-20 expression modulates some ATRA-regulated signaling molecules. 
A: HL-60 cells or CD38 Δ11-20 cells were treated or not with ATRA for 48 hours and Western 
blot analysis for ERK phosphorylation was performed with total ERK used as a loading control. 
B: Western blot for Fgr expression after 48 hours of ATRA treatment or untreated culture. 
GAPDH was used as a loading control. C: Western blot of Vav1 expression after 48 hours of 
ATRA treatment or untreated culture. GAPDH was used as a loading control. 
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HL-60 cells and CD38 Δ11-20 transfectants were ATRA-treated or left untreated for 48 hours, 
and phosphorylated ERK1/2 was assessed (Figure 2.5a). The CD38 Δ11-20 transfectants showed 
enhanced ERK activation compared to HL-60 cells. ATRA increased activated ERK in both 
cases with CD38 Δ11-20 cells still exceeding HL-60. Hence the CD38 Δ11-20 cells were still 
capable of producing a persistent cellular MAPK signal, but it did not propel ATRA-induced 
differentiation. 
While CD38 Δ11-20 appears to be capable of generating a MAPK signal, its inhibitory effect on 
ATRA-induced differentiation suggests that this signaling differs from that of wild-type CD38.  
One such possibility is disruption of MAPK regulators such as Src family kinases and the 
guanine nucleotide exchange factor Vav1 [39-42]. ATRA upregulates Fgr and Vav1 [43, 44], 
and Vav1 interacts with CD38 through a c-Cbl containing complex [14]. This motivated interest 
in the effect of CD38 Δ11-20 on Fgr and Vav1. 
Fgr upregulation is proposed to prevent apoptosis and promote granulocytic differentiation [43, 
45]. Therefore, Fgr may be important for ATRA-induced signaling mechanisms and cell survival 
through maturation. Treated HL-60 cells showed upregulated expression of Fgr while CD38 
Δ11-20 cells did not (Figure 2.5b). Premature cell death was not observed with Trypan Blue 
exclusion staining nor was the presence of sub-G1 populations detectable by flow cytometry 
(data not shown), indicating the cells were not experiencing elevated apoptosis. These results 
implied that the expression of CD38 Δ11-20 interfered with the expected ATRA-induced Fgr 
upregulation. 
Vav1, a guanine nucleotide exchange factor (GEF) for the Rho family of Ras-related GTPases, 
becomes upregulated [44] after ATRA treatment in HL-60 cells and can be phosphorylated by 
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Fgr [46]. After 48 hours of ATRA, HL-60 cells showed a modest increase in total Vav1 
expression (Figure 2.5c). However, there was no change in Vav1 expression in CD38 Δ11-20 
cells. These results indicated that ATRA-induced Vav1 upregulation was also defective when 
CD38 Δ11-20 was expressed.  
2.5 Discussion 
CD38 is a membrane-expressed protein that is used as a prognostic indicator in leukemia. While 
it is often considered a negative marker in chronic lymphocytic leukemia (CLL), the 
consequences of CD38 expression are somewhat enigmatic in acute myelogenous leukemia 
(AML). Because CD38 is associated with signaling mechanisms that may induce proliferation, 
differentiation, or apoptosis [22, 27, 47] the role of CD38 in cell survival and terminal arrest 
remains ambiguous. This could reflect the diversity of its functions and capabilities. 
CD38 is known to have both enzymatic and receptor functions. The extracellular domain is able 
to catalyze the formation of cADPR and NAADP+, which are both calcium-mobilizing second 
messengers. CD38 also participates in a variety of signaling events by serving as a ligand-
activated receptor and by forming lateral associations with other proteins at the cell membrane. 
Here we attempt to segregate several of these functions and determine which are important for 
ATRA-induced myeloid differentiation in HL-60 human leukemia cells. We find that a cytosolic 
deletion mutant (CD38 Δ11-20) which does not membrane express interrupted differentiation, as 
evidenced by a lack oxidative metabolism, insignificant growth arrest, and decreased CD11b 
expression. Expression of CD38 Δ11-20 also caused failure to upregulate markers including Fgr 
and Vav1 which are induced by ATRA and may be MAPK modulators. In contrast, crippling 
enzymatic activity by inhibitors had no effect on ATRA-induced myeloid differentiation. Also, 
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cells expressing catalytically inactive CD38 showed similar enhanced differentiation as cells 
expressing wild-type CD38. 
CD38 Δ11-20 transfectants failed to show ATRA-induced G1/0 enrichment and oxidative 
metabolism, suggesting that they are unable to undergo respiratory burst and growth arrest 
characteristic of terminal differentiation. Src family tyrosine kinases such as Fgr, which is 
expressed in differentiated myeloid cells after ATRA treatment, mediate respiratory burst [46, 
48]. Fgr failed to up-regulate in ATRA-treated CD38 Δ11-20 cells. The transfectants also 
showed decreased ATRA-induced expression of CD11b, an α-integrin receptor subunit. Treating 
HL-60 cells with molecules that upregulate CD11b increases inducible oxidative metabolism [6, 
49]. Membrane-localized Fgr plays a role in integrin receptor signaling [50], and integrin 
signaling may be important for hematopoietic myelo-monocytic differentiation [51, 52]. This 
suggests that the compromised induced expression of both Fgr and CD11b may decrease the 
oxidative metabolism capability in CD38 Δ11-20 cells that is normally characteristic of 
differentiated myelocytes.  
CD38 Δ11-20 expression also disrupted ATRA-induced expression of Vav1, which is tyrosine 
phosphorylated by Fgr [46]. Vav1 is a Rho/Rac GEF that also regulates PI3K activity during 
myeloid differentiation [45, 53] and MAPK signaling in lymphocytes [39, 40]. Overexpression 
of Vav1 enhances myeloid differentiation and coincides with nuclear translocation of its 
tyrosine-phosphorylated form and nucleoskeleton rearrangement [44, 54]. ATRA-treated HL-60 
cells showed an increase in Vav1 expression compared to untreated cells, while CD38 Δ11-20 
transfectants did not.  
The MAPK signaling cascade is also activated in HL-60 cells after ATRA treatment and is 
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required for differentiation progression [19, 55]. In CD38 Δ11-20 transfectants ERK 
phosphorylation was enhanced after 48 hours of ATRA treatment but cell differentiation was 
inhibited. These results indicate that while MAPK signaling is necessary, it is not sufficient in 
itself for ATRA-induced differentiation. It is possible that CD38 Δ11-20 is changing the 
character of the MAPK cascade and affecting cellular outcomes by disrupting MAPK signaling 
regulators, which may include Vav1, Fgr, and other molecules. The MAPK network employs 
numerous adaptor, scaffolding, and inhibitory accessory proteins that regulate signaling; and 
direct MAPK signaling effectors such as Raf, MEK, and ERK may also serve as scaffolds, 
adaptors, and inhibitors themselves to finely tune the outcome of MAPK signaling (reviewed in 
[56]). Therefore CD38 Δ11-20, or ATRA-modulated signaling molecules that are not 
upregulated in CD38 Δ11-20 cells, could be aberrantly interacting with or affecting the 
regulation of signaling networks such as MAPK that are important for myeloid differentiation 
induction. It is also possible that CD38 Δ11-20 itself may disrupt protein-protein interactions 
with ATRA-induced, endogenous membrane CD38 and its downstream effectors, thus crippling 
wild-type signaling. Further research will be needed to elucidate how the CD38 Δ11-20 deletion 
mutant inhibited differentiation, but the discovery that it appears to act as a dominant negative is 
noteworthy. While the results in this study support the notion that CD38 plays a direct role in 
differentiation, we cannot rule out the possibility that the proteins affected by CD38 Δ11-20 
expression, such as CD11b, Fgr, and Vav1, either act independently or as accessory signaling 
proteins, and their disruption interferes with differentiation. 
In contrast, crippling enzymatic cADPR catalytic activity, either by treatment with a specific 
small molecule inhibitor or by site-directed mutagenesis, does not impair ATRA-induced 
differentiation progression. WT38 and CD38 E226Q transfectants that overexpress wild-type or 
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catalytically inactive protein, respectively, show similar enhanced differentiation compared to 
parental HL-60 cells. Regulation of ATRA-induced differentiation by CD38 thus does not appear 
to depend on its ectoenzyme activity. The results of other studies are consistent with this 
premise. CD38 enzymatic activity and receptor functions are uncoupled in a murine pro-B 
leukemic cell line. Receptor signaling cascades show dependence on downstream tyrosine kinase 
activity but are independent of ADP-ribosyl cyclase and NAD-glycohydrolase mechanisms [27, 
57].  
In conclusion, these results suggest that membrane-expressed CD38 may be required for the 
regulation and activation of downstream signaling mechanisms induced by ATRA treatment, 
which a non-membrane, cytosolic deletion mutant blocks. CD38 apparently promotes ATRA-
induced myeloid differentiation through its receptor but not ecto-enzymatic functions. 
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CHAPTER III 
THE CD38 Δ11-20 MUTANT CRIPPLES ATRA-INDUCED GRANULOCYTIC 
MATURATION BUT NOT 1,25-DIHYDROXYVITAMIN D3-INDUCED MONOCYTIC 
DIFFERENTIATION 
 
3.1 Abstract 
HL-60 human myeloid leukemia cells are biopotent and differentiate to neutrophils or monocytes 
after treatment with all-trans retinoic acid (ATRA) or 1,25-dihydroxyvitamin D3, respectively. A 
previous report shows that cells expressing a CD38 cytosolic mutation (CD38 Δ11-20) fail to 
differentiate after ATRA treatment, evidenced by crippled upregulation of differentiation 
markers such as CD11b and failure to G1/0 arrest. Here we report that CD38 Δ11-20 cells are 
capable of monocytic differentiation induced by D3, evidenced by expression of CD11b and 
G1/0 arrest that is similar to wild-type parental HL-60 cells. These results show that CD38 Δ11-
20 cells are responsive to D3 but not to ATRA, and suggests that membrane-expressed, wild-
type CD38 is important for ATRA induction but not monocytic maturation propelled by D3. 
3.2 Introduction 
Bipotent HL-60 myeloid leukemia cells differentiate along the granulocytic lineage when treated 
with all-trans retinoic acid (ATRA) and undergo monocytic maturation when treated with 1,25-
dihydroxyvitamin D3 (D3). Treatment with either agent causes increases in CD11b, CD14, and 
CD38 expression, and G1/0 arrest.  D3 treatment results in more CD11b and CD14 expression 
and less CD38 expression compared to ATRA [1, 2]. D3 and ATRA induction both depend on 
MAPK signaling through the c-Raf/MEK/ERK axis [3-6]. CD38 and one of its partner 
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molecules, c-Cbl, both drive MAPK signaling and differentiation when overexpressed [7-9]. 
Therefore CD38 and its accessory molecules may propel signaling necessary for both ATRA and 
D3 induction. 
A stable transfectant cell line expressing a CD38 cytosolic tail truncation that is not membrane 
expressed (CD38 Δ11-20) shows defective ATRA-induced differentiation. This is evidenced by 
decreased G1/0 arrest and oxidative metabolism capability, and crippled upregulation of 
differentiation markers including CD11b, Vav1, and Fgr [10]. The data suggest that wild-type 
membrane CD38 is required for ATRA-induced myeloid differentiation and motivated interest in 
whether or not CD38 Δ11-20 cells were also defective in D3-induced monocytic differentiation. 
We confirmed previous data showing that CD38 Δ11-20 cells treated with ATRA exhibited 
crippled CD11b expression and G1/0 arrest. However, after D3 treatment CD38 Δ11-20 
transfectants showed CD11b expression and G1/0 arrest similar to treated parental HL-60 cells. 
This indicates that wild-type membrane CD38 is required for ATRA-induced granulocytic 
differentiation but not for D3-induced monocytic maturation, and suggests that the efficacy of 
D3 treatment does not depend on CD38 expression or its receptor signaling functions.  
3.3 Materials and Methods 
Cell culture. HL-60 human myeloblastic leukemia cells and CD38 Δ11-20 stable transfectant 
cells were grown
 
in RPMI 1640 supplemented with 5% heat-inactivated fetal bovine
 
serum 
purchased from Invitrogen (Carlsbad, CA) in a 5% CO2 humidified atmosphere at 37
o
C. CD38 
Δ11-20 stable transfectants were created as described [10]. ATRA was purchased from Sigma 
(St. Louis, MO) and solubilized in ethanol. Cells were treated with a final concentration of 1 µM. 
1,25-dihydroxyvitamin D3 was purchased from Sigma and solubilized in ethanol. Cells were 
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treated with a final concentration of 5 µM.  
Flow Cytometry. Immunostaining for CD11b with antibody from BD Pharmingen (San Jose, 
CA) was performed as previously described using a Becton Dickinson LSR II flow cytometer 
(San Jose, CA) [8]. Gating was set to exclude 95% of the negative control. Propidium
 
iodide (PI) 
cell cycle analysis was performed as previously described [8]. 
3.4 Results 
 3.4.1 CD38 Δ11-20 cells show CD11b expression comparable to wild-type HL-60 cells after 
treatment with D3 but not ATRA. First we evaluated expression of the differentiation marker and 
α-integrin receptor CD11b. CD11b is detectable within 24 hours of ATRA- or D3-treatment and 
increases in expression over time, with D3 showing enhanced expression compared to ATRA. 
Since CD38 Δ11-20 transfectants display crippled CD11b expression after ATRA, we evaluated 
if this was also the case after D3 treatment. We evaluated CD11b by flow cytometry after the 
indicated treatments and time points (Figure 3.1). Untreated HL-60 and CD38 Δ11-20 cells show 
negligible CD11b at all time points. ATRA and D3 treated HL-60 cells show elevated expression 
within 24 hours of treatment; an approximate 20% and 40% increase compared to the untreated 
control, respectively. Expression continues to increase over time, with D3 showing enhanced 
expression as anticipated for wild-type HL-60 cells. However, while ATRA-treated CD38 Δ11-
20 cells show crippled CD11b expression, D3 treatment results in CD11b levels comparable to 
D3-treated parental HL-60 cells after 48 hours. Therefore unlike ATRA, D3 treatment is able to 
facilitate upregulation of the differentiation marker CD11b in CD38 Δ11-20 cells.  
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Figure 3.1 CD38 Δ11-20 cells treated with D3 show CD11b expression similar to wild-type 
HL-60 cells. Cells were immunostained for CD11b at the indicated time points. Gating was set 
to exclude 95% of the negative control (untreated HL-60 cells) for each time point. (*p=<0.05 
significantly higher than untreated HL-60 cells at the same time point.) 
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3.4.2 CD38 Δ11-20 cells treated with D3 are capable of cell cycle arrest. HL-60 and CD38 Δ11-
20 cells were either left untreated or treated with D3 or ATRA, and after 72 hours G1/0 
enrichment was evaluated (Figure 3.2). HL-60 cells treated with ATRA or D3, and CD38 Δ11-20 
cells treated with D3, show significant G1/0 enrichment compared to untreated controls (Figure 
3.2). However CD38 Δ11-20 cells treated with ATRA have a significantly lower percentage of 
cells in G1/0 than all other ATRA- or D3-treated samples. Therefore, CD38 Δ11-20 cells were 
capable of cell cycle arrest after D3 treatment but not ATRA. 
3.5 Discussion 
CD38 is a leukocyte antigen known to propel ATRA-induced myeloid maturation and MAPK 
signaling that is necessary for differentiation [7]. Wild-type, membrane-expressed CD38 appears 
to be required for ATRA’s efficacy, since CD38-targeted siRNA interferes with differentiation 
and a cytosolic mutant (CD38 Δ11-20) that fails to membrane express likewise cripples the 
effects of ATRA [10, 11]. However whether or not CD38 is important for D3-induced monocytic 
differentiation is unknown. We used CD38 Δ11-20 stable transfectants that show little response 
to ATRA and treated them with D3 to evaluate if they reacted to a monocytic inducer.  
Surprisingly, we found that CD38 Δ11-20 cells responded to D3 similar to wild-type HL-60 
cells, and were capable of CD11b upregulation and G1/0 arrest. Therefore, expression of a 
mutant non-membrane CD38 protein that disrupts ATRA induction did not interfere with the 
effects of D3. These results indicate that CD38 and its receptor signaling functions may not be 
important for D3-induced differentiation.  
The results also suggest that early cell signaling events during the first 24 hours of ATRA  
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Figure 3.2 CD38 Δ11-20 cells treated with D3 show G1/0 cell cycle arrest comparable to 
wild-type HL-60 cells. Cells were treated as indicated for 72 hours and cell cycle was measured 
using flow cytometry and propidium iodide staining. (*p=<0.05 G1/0 phase was significantly 
enriched compared to untreated HL-60 cells; $=p<0.05 G1/0 phase significantly lower than all 
other samples that received ATRA or D3 treatment.)  
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treatment, such as those propelled by CD38, are lineage-specific. A previous report proposes that 
early cellular events and signaling are not specific to lineage, since 24 hours of ATRA treatment 
followed by 24 hours of D3 results in monocytic differentiation and vice versa [12]. In contrast, 
the data presented here indicates that early events, including the expression of CD38 and the 
signaling cascades it regulates, may be important or not depending on lineage.  
The mechanism by which CD38 Δ11-20 cripples ATRA induction requires additional 
investigation, and could illuminate protein interactions and signaling pathways that distinguish 
granulocytic maturation from monocytic. For example, different molecules could be involved in 
lineage-specific MAPK signaling propagation. CD38 drives MAPK signaling, and both drive 
granulocytic differentiation. While D3 also requires a persistent MAPK signal, that signal may 
be regulated by a different ensemble of molecules. Also, proteins associated with membrane-
expressed CD38 and drive ATRA-induced differentiation (which could be misregulated or 
sequestered by CD38 Δ11-20) may not be important for monocytic differentiation induced by 
D3. In this case CD38 Δ11-20 may not impede the effects of D3. CD38-modulated proteins 
could include c-Cbl, which associates with CD38 and also drives MAPK signaling, and c-Cbl 
partners such as Vav1 and SLP-76 that also appear to regulate granulocytic differentiation. 
Future research may focus on the identification of CD38-associated molecules that are important 
for ATRA induction, and elucidate if they impinge on D3-induced differentiation. 
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CHAPTER IV 
LOSS OF DIFFERENTIATION PRECOMMITMENT MEMORY CORRESPONDS TO 
THE LOSS OF CD38 AND p-ERK PARENT-TO-DAUGHTER HERITABILITY  
 
 
4.1 Abstract 
Continuous treatment of HL-60 acute myeloblastic leukemia cells with all-trans retinoic acid 
(ATRA) causes terminal differentiation along the granulocytic lineage. During the first 24 hours 
cells show early markers of phenotypic conversion including ERK phosphorylation and 
expression of CD38, which is known to drive MAPK signaling. Previous results show that after 
48 hours cells are committed to differentiation and show signs of late myeloid maturation 
including G1/0 arrest and inducible oxidative metabolism. A preceding study reports that 24-
hour exposure to ATRA followed by drug removal results in the acquisition of a semi-stable 
precommitment memory, where abbreviated re-exposure to ATRA induces late differentiation 
markers. This memory precommitment is lost after three cell division cycles. Here we report the 
loss of precommitment memory temporally corresponds with the loss of CD38 and p-ERK 
parent-to-daughter heritability. After three division cycles following ATRA removal cells 
showed inherited CD38 and p-ERK but lost the ability to confer expression to daughter cells, 
since after four divisions cells showed crippled CD38 expression and p-ERK comparable to 
control. This suggests that CD38 may drive MAPK signaling which contributes to the 
maintenance of a heritable precommitment state where cells are “primed” for differentiation. 
4.2 Introduction 
Continuous treatment of HL-60 acute myelogenous leukemia cells with ATRA results in 
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terminal differentiation along the granulocytic lineage. After two cell division cycles (48 hours) 
of ATRA exposure, HL-60 cells are committed to terminal differentiation evidenced by G1/0 
arrest and later signs of phenotypic conversion including inducible oxidative metabolism [1, 2]. 
During the first 24 hours of ATRA exposure cells exhibit early markers of induced 
differentiation such as CD38 and ERK phosphorylation, but no evidence of G1/0 arrest or other 
late markers. HL-60 cells that have undergone 24 hours of ATRA exposure are characterized as 
precommitted and are “primed” to differentiate.  For example, if ATRA is withdrawn after one 
cell division (24 hours), HL-60 cells will continue to grow exponentially and fail to terminally 
differentiate. However reintroduction of ATRA during up to three cell division cycles (24, 48, or 
72 hours) post-ATRA withdrawal results in significant differentiation after one cell cycle, 
characterized by G1/0 arrest and inducible respiratory burst [1-5]. Therefore cells seem to retain 
a “commitment memory” after the initial ATRA exposure which is heritable but labile, since 
after three divisions (96 hours) cells are no longer primed and require the full 48 hours of ATRA 
retreatment to show evidence of late differentiation. 
The semi-stable precommitment state is characterized by structural changes to the nucleus [1, 2], 
and one report suggests it is not lineage-specific [6]. This study shows that sequential treatment 
of HL-60 cells with the monocytic inducer 1,25-dihydroxyvitamin D3 (D3) for 24 hours 
followed by ATRA (a granulocytic inducer) results in granulocytic differentiation and vice versa, 
suggesting that the differentiation lineage is decided by late exposure to the inducing agent. 
However data presented in Chapter 3 indicate that some early events, including CD38-driven 
signaling, may have lineage-specific roles.  
Since early treatment over the course of one cell division primes cells for terminal 
differentiation, it is important to elucidate which signaling molecules may regulate the 
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maintenance of precommitment memory. CD38 is an early marker of ATRA-induced 
differentiation (detectable 6 hours after treatment) that drives MAPK signaling when 
overexpressed [7]. MAPK signaling evidenced by modifications of the Raf/MEK/ERK axis is 
reported to be required for ATRA effectiveness, since inhibitors of MEK and c-Raf suppress 
differentiation [8, 9]. CD38 itself is also thought to play a causal role in ATRA induction since 
overexpression propels myeloid maturation, while a cytosolic mutant that is not membrane-
expressed or siRNA targeting CD38 cripples the effects of ATRA treatment [10, 11]. There is 
also evidence that CD38 may be involved in a positive feedback loop that sustains MAPK 
signaling (Tasseff et al., unpublished). 
We tracked changes in the expression of CD38 and ERK phosphorylation status over time after 
“priming” HL-60 cells with ATRA for 24 hours and then withdrawing treatment. We found that 
CD38 expression exceeded 80% of the untreated control for three cell divisions after ATRA 
removal, indicating that the proliferating cells sustained CD38 expression. When cells had 
completed four division cycles (96 hours post-ATRA removal) CD38 was still expressed at 
levels that were approximately 75% of the untreated control but these cells were not capable of 
giving rise to daughter cells with high CD38 expression. This corresponds to the loss of 
precommitment memory, since cells reintroduced to ATRA at 96 hours require a full 48 hours of 
re-treatment to show late differentiation markers. After the fifth division CD38 expression 
dropped to levels comparable to control. Likewise, heritable ERK phosphorylation was persistent 
for 96 hours after ATRA removal, but then fell to levels similar to the untreated control, 
indicating that parent-to-daughter p-ERK heritability was lost. Therefore, the significant decrease 
in the ability of parental HL-60 cells to sustain CD38 and p-ERK expression followed a time 
course similar to HL-60 precommitment loss. This suggests CD38 drives MAPK signaling to 
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maintain a cellular ATRA exposure memory and the ability to remain “primed” for 
differentiation.  
4.3 Materials and Methods 
Cell culture. HL-60 cells were grown
 
in RPMI 1640 with 1% antibiotic/antimycotic from 
Invitrogen (Carlsbad, CA) and treated with 1 µM ATRA as previously described [10]. For 
precommitment experiments cells were treated with ATRA for 24 hours, washed 3x to remove 
ATRA, and reseeded every 24 hours at 0.2x10
6
/mL in ATRA-free media as described.  
Antibodies and reagents. Antibody for cytometric analysis of CD38 was purchased from BD 
Pharmingen (San Jose, CA). p-Erk1/2 and GAPDH were purchased from Cell Signaling 
(Danvers, MA). Protease and phosphatase inhibitors, and dimethyl sulfoxide (DMSO) were 
purchased from Sigma Aldrich (St. Louis, MO). M-PER Mammalian Protein Extraction Reagent 
lysis buffer was purchased from Pierce (Rockford, IL). 
Flow cytometric phenotypic analysis. Immunostaining for CD38 was performed by treating 
1x10
6
 or 0.5x10
6
 cells with antibody (concentration per manufacturer’s instructions) for one hour 
in PBS at 37
o
C. Fluorescence was detected using a Becton Dickinson LSR II flow cytometer 
(San Jose, CA) as previously described [12]. Gating for positive cells was set to exclude 95% of 
the negative control. 
Western blot analysis. Cells were lysed and subjected to standard SDS-PAGE analysis as 
previously described [10].  
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4.4 Results 
4.4.1 CD38 heritability is synchronized with ATRA precommitment sensitivity. Since cells treated 
with ATRA for 24 hours are primed for differentiation and show a precommitment sensitivity, 
we monitored changes in CD38 expression after ATRA withdrawal to evaluate if there were 
time-dependent similarities to precommitment memory maintenance. We treated HL-60 cells 
with ATRA for 24 hours and then reseeded them in ATRA-free media. HL-60 expression of 
CD38 remained high through the first four cell divisions (96 hours) after ATRA removal: 
approximately 95% of the negative control at 24 hours, 90% at 48 hours, 80% at 72 hours, and 
75% at 96 hours (Figure 4.1a&b). Interestingly after three divisions (96 hours) parent cells are no 
longer able to impart high CD38 expression to daughter cells, since at 120 hours post-ATRA 
removal CD38 expression significantly decreased to 40% indicating dilution by cell division. 
CD38 expression was similar to control after five divisions. The loss of CD38 parent-to-daughter 
heritability therefore corresponded temporally with the loss of precommitment memory.  
4.4.2 Parent-to-daughter conferral of ERK phosphorylation is concurrent with loss of CD38 
heritability and precommitment memory. Since MAPK signaling is required for ATRA-induced 
differentiation and CD38 drives ERK activation, we monitored ERK phosphorylation status after 
a 24 hour pulse exposure to ATRA followed by removal. Similar to CD38 expression, cells 
showed inherited ERK phosphorylation through the first four divisions, but after that parental 
cells were unable to confer p-ERK expression to daughter cells (Figure 4.2). Therefore, after four 
divisions (120 hours) post-ATRA removal cells no longer showed high CD38 or p-ERK 
inheritance. This raises the possibility that the significant decrease in CD38 expression may have 
contributed to the loss of ERK phosphorylation.  
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Figure 4.1 Parent cells do not confer high CD38 expression to daughter cells 96 hours post-
ATRA removal. A: Flow cytometry histograms for CD38 show decreasing expression after 
ATRA removal. B: CD38-positive expression post-ATRA removal. Gating was set to exclude 
95% of the negative control.  
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Figure 4.2 Loss of heritable ERK phosphorylation coincides with loss of precommitment 
memory. Western blot for p-ERK at indicated time points. GAPDH was used as a loading 
control. 
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Discussion 
CD38 expression and ERK phosphorylation are early markers of ATRA-induced myeloid 
differentiation, and CD38 drives MAPK signaling [7]. Within 24 hours of ATRA exposure HL-
60 cells also develop a precommitment memory and are “primed” for differentiation. This 
precommitted state persists for three division cycles post-ATRA withdrawal, evidenced by 
detectable late differentiation markers after only 24 hours of ATRA reintroduction. Therefore 
cells that are re-exposed to ATRA 24, 48, or 72 hours after removal are “primed” for 
differentiation. However, if cells are re-exposed 96 hours after the initial ATRA treatment, 
differentiation requires a full 48 hours of ATRA reintroduction, similar to untreated cells [1]. 
This phenomenon suggests there are early events after ATRA treatment that are important for 
maintenance of a labile precommitment memory. This motivated interest in whether changes in 
the expression of early ATRA-induced markers, such as CD38 and p-ERK (which may be driven 
by CD38), show parallelism to the gain and loss of a precommitted state.  
We found that the loss of the parental cells’ ability to sustain high heritable expression of CD38 
or phosphorylated ERK corresponded with the loss of precommitment memory. For three 
division cycles after ATRA withdrawal, parent cells were able to impart CD38 and p-ERK 
expression to daughter cells. Although high CD38 expression was inherited through four division 
cycles after ATRA exposure, after the third division parent cells could not give rise to daughter 
cells with CD38 high expression. This coincided with the loss of p-ERK parent-to-daughter 
heritability.  
These results suggest that CD38 signaling, which drives ERK phosphorylation, may support the 
maintenance of the precommitment memory state. CD38 signaling is reported to be important for 
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ATRA effectiveness, since siRNA targeted against CD38 and a cytosolic mutant that is not 
membrane expressed (CD38Δ11-20) both interrupt ATRA-induced differentiation [10, 11]. 
Similarly, MAPK signaling inhibitors cripple ATRA induction [8, 9]. The data are consistent 
with a model whereby ATRA induces CD38 expression to generate a MAPK signal. This 
sustains a precommitment memory during three cell divisions, which regulates the maintenance 
of a state where HL-60 cells are “primed” for differentiation. 
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CHAPTER V 
 
LYN KINASE ACTIVITY REGULATES ATRA-INDUCED AND CD38-PROPELLED 
PHOSPHORYLATION OF c-CBL AND p85 PI3K 
 
5.1 Abstract 
The leukocyte antigen CD38 is expressed after all-trans-retinoic acid (ATRA) treatment in HL-
60 myelogenous leukemia cells and promotes induced myeloid differentiation when 
overexpressed.  We found that Vav1 and SLP-76 associate with CD38 in two cell lines, and that 
all three of these proteins complex with Lyn, a Src family kinase (SFK) upregulated by ATRA. 
We used the SFK inhibitor PP2 to evaluate if CD38-driven signaling depends on Lyn kinase 
activity. Cells treated with ATRA for 48 hours followed by one hour of PP2 incubation show 
SFK/Lyn kinase inhibition. We observed that Lyn inhibition blocks c-Cbl and p85/p55 PI3K 
phosphorylation driven by the CD38 agonist IB4 in ATRA-treated HL-60 cells and untreated 
CD38+ transfectants. In contrast, cells treated with ATRA and PP2 at the same time and then 
cultured for 48 hours did not show Lyn inhibition, therefore ATRA protected Lyn from the 
effects of PP2. 48 hours of co-treatment also preserved CD38-stimulated c-Cbl and p85/p55 
PI3K phosphorylation indicating Lyn kinase activity is necessary for these events. Another SFK 
inhibitor (dasatinib) which blocks Lyn activity with ATRA co-treatment prevented ATRA-
induced c-Cbl phosphorylation and crippled p85 PI3K phosphorylation, indicating Lyn kinase 
activity is important for ATRA-propelled events which may be regulated by CD38. We also 
found that the loss of Lyn activity coincided with a decrease in Vav1/Lyn/CD38 and SLP-
76/Lyn/CD38 interaction, suggesting these molecules form a complex that regulates CD38 
signaling. Lyn inhibition also reduced Lyn and CD38 binding to p85 PI3K, indicating CD38 
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facilitates a complex responsible for PI3K phosphorylation. Therefore Lyn kinase activity is 
important for CD38-associated signaling that may drive ATRA-induced differentiation. 
5.2 Introduction 
All-trans retinoic acid (ATRA) is used clinically to treat acute promyelocytic leukemia (APL), 
but is largely unsuccessful in treating other types of leukemias that are t(15,17) negative. HL-60 
is a human acute myelogenous leukemia (AML) cell line that is t(15,17)  negative and used as a 
model to study the mechanisms of ATRA-propelled myeloid differentiation in non-APL cells. 
Molecules and signaling pathways that confer ATRA responsiveness in HL-60 cells may be 
important in elucidating how a non-APL leukemia cell can be induced to differentiate by ATRA, 
and may ultimately provide knowledge that could expand the use of ATRA as a therapeutic 
agent. 
CD38 is a leukocyte antigen that is an early marker of ATRA induction and drives differentiation 
when overexpressed [1]. CD38 has enzymatic activity that generates the Ca
2+
 mobilizing 
compounds NAADP+ and cADPR. It also has receptor functions that drive cell signaling 
including the phosphorylation of c-Cbl, ERK, and the p85 PI3K regulatory subunit [1-8].  
Enzymatic activity and receptor/signaling functions can operate independently [9-11].  For 
example, CD38 metabolic activity is unnecessary for ATRA-induced differentiation while the 
receptor function associated with membrane-expressed CD38 is required [12]. In addition, 
siRNA targeting CD38 cripples differentiation [13]. These reports suggest that CD38-driven 
signaling is important for ATRA-driven myeloid maturation. Therefore, it is of interest to 
identify CD38-associated signaling molecules and how they may regulate ATRA efficacy. Such 
knowledge may indicate targets for therapeutic intervention. 
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CD38 forms a complex with c-Cbl [14, 15] and CD38 agonist ligand interaction results in c-Cbl 
phosphorylation [2]. c-Cbl is an E3 ubiquitin ligase and adaptor molecule that, like CD38, 
promotes MAPK signaling and ATRA-induced differentiation when overexpressed [2, 14, 15]. 
This suggests that the c-Cbl/CD38 interaction may cooperatively drive MAPK signaling and 
other aspects of ATRA therapy. This is consistent with a report that a c-Cbl tyrosine kinase 
binding (TKB) domain mutant (G306E) that does not bind CD38 also fails to drive MAPK 
signaling and differentiation [15].  
c-Cbl is known to interact with the guanine nucleotide exchange factor (GEF) Vav1, the SLP-76 
adaptor, and, like CD38, the p85 regulatory subunit of PI3K [14-17]. c-Cbl, SLP-76, and Vav1 
protein expression and p85 PI3K activity are upregulated during granulocytic maturation [18-
22]. These four proteins also form complexes in myeloid cells after ATRA treatment. For 
example, Vav1 associates with PI3K and may facilitate the characteristic nucleoskeleton 
remodeling that occurs with ATRA treatment in HL-60 and NB4 cells [23, 24]. Consistent with 
this, downmodulation of Vav1 impedes induced myeloid maturation and nucleoskeleton 
remodeling, and affects differentiation-related protein expression [22]. This suggests Vav1 may 
be a key regulator of myeloid differentiation.  
The Src homology 2 domain of Vav1 interacts with c-Cbl and SLP-76 in a differentiation-
dependent manner. After ATRA treatment Vav1/c-Cbl complexes are detectable in the cytosol, 
while Vav1/SLP-76 interactions are predominant in nuclei [23]. SLP-76 is also upregulated after 
ATRA and forms a complex with c-Cbl [15]. Co-expression of SLP-76 with CSF-1/c-FMS 
enhances ATRA-induced ERK activation, G0 cell cycle arrest, and a number of additional 
differentiation markers [20].  
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CD38 agonist ligation by the m(Abs) IB4 and T16 induces phosphorylation of the p85 regulatory 
subunit of PI3K and is associated with normal and leukemic B cell growth suppression [25-27]. 
Consistent with this, PI3K inhibitors relieved CD38-mediated growth suppression in ATRA-
treated HL-60 cells [28], which suggests a PI3K-modulated CD38 feedback loop.  
CD38 also drives transient MAPK activation after agonist ligation, which is orchestrated by the 
Raf/MEK/ERK axis [5, 6]. Transient or protracted signaling from this cascade can lead to either 
cell proliferation or differentiation respectively [29], and sustained MAPK signaling 
characterizes ATRA-induced differentiation [30, 31]. CD38 overexpression results in persistent 
ERK phosphorylation, therefore CD38 appears capable of propagating a transient or sustained 
MAPK signal. 
Lyn and other SFKs are known to be modulated by ATRA treatment, and Lyn is linked to CD38-
driven signaling events. For example, CD38 stimulation of B lymphocytes obtained from Lyn-
deficient mice showed defective differentiation, and drugs interfering with PI3K or ERK 
decreased differentiation [32]. This suggests that Lyn may cooperate with other CD38-associated 
signaling molecules, such as PI3K and ERK.  Other reports show that both Fyn and Lyn are 
required for B cell signaling after CD38 ligation [33]. Likewise, in lymphoblastoid B-cell 
membrane rafts CD38 is associated with Lyn and modulates cell signaling [34]. 
SFK inhibitors are known to enhance aspects of ATRA induction, including expression of 
CD11b and other myeloid maturation markers [35, 36]. A recent study reported that dasatinib, 
which inhibits Lyn kinase activity alone and with ATRA co-adminstration, enhances 
differentiation (Congleton et al., in press). However the inhibitor PP2, which inhibits Lyn alone 
but does not block kinase activity with ATRA co-treatment, shows a more significant 
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enhancement of ATRA-induced differentiation than dasatinib. Therefore, Lyn kinase activity 
may function to drive some aspects of differentiation.  
Since membrane-expressed CD38 has a role in differentiation, signaling that may involve c-Cbl, 
SLP-76, Vav1, PI3K, and Lyn are important in understanding how ATRA provides therapeutic 
benefit. Clarification of pathways that confer ATRA responsiveness in t(15,17) negative HL-60 
cells could lead to new treatment targets in a larger array of leukemias, as well as other types of 
cancers. For example, ATRA has shown some promise in treating reproductive leiomyomas by 
modulating the PI3K signaling cascade [37]. 
Our results show that CD38, SLP-76, and Vav1 were able to interact together in two cell lines, 
HL-60 and NB4. Lyn also complexed with these molecules and we evaluated if Lyn kinase 
activity had an effect on CD38 ligand-induced signaling, including phosphorylation of c-Cbl, 
ERK, and p85 PI3K. Using the SFK inhibitor PP2 we found that blocking Lyn kinase activity 
had no effect on ERK phosphorylation, but was able to completely abrogate c-Cbl and p85 PI3K 
phosphorylation driven by the CD38 agonist IB4 [27, 38]. We used CD38+ stable transfectants 
and ATRA-treated HL-60 cells to evaluate if the effects of the inhibitor were associated with 
either ATRA or CD38 expression alone, and found that PP2 blocked pY-c-Cbl and pY-p85 PI3K 
in both cell lines. A previous report showed that co-treatment with ATRA and PP2 followed by 
48 hours of culture protects Lyn kinase activity from PP2 inhibition and significantly enhances 
differentiation (Congleton et al., in press). Protecting Lyn kinase activity using ATRA/PP2 co-
treatment also permitted CD38 ligand-induced phosphorylation of c-Cbl and p85 PI3K. We also 
observed that dasatinib, which unlike PP2 blocks Lyn activity with ATRA co-treatment, 
prevented ATRA-propelled c-Cbl phosphorylation and crippled p-p85 PI3K. Therefore Lyn 
activity appears needed for two signaling events that are downstream of CD38 and induced by 
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retinoic acid. 
Finally, we observed that inhibition of Lyn decreased interactions among Vav1/Lyn/CD38, SLP-
76/Lyn/CD38, and p85 PI3K/Lyn/CD38. Importantly, the p85 PI3K/Lyn/CD38 association 
correlates with p85 phosphorylation. These results suggest that the loss of Lyn activity interrupts 
interactions in a proposed CD38-facilitated signaling complex that involves SLP-76, Vav1, and 
Lyn, and that this complex regulates the downstream phosphorylation of c-Cbl and p85 PI3K. 
The observed interaction between p85 PI3K, Lyn, and CD38 suggests that CD38 has direct role 
in assembling a Lyn kinase-containing complex that phosphorylates p85 PI3K. Together these 
results indicate that Lyn kinase activity regulates CD38 signaling which results in pY-c-Cbl and 
pY-p85 PI3K, which is associated with ATRA induction and PP2-enhanced differentiation. 
These outcomes are important in understanding how the CD38 receptor functions during 
differentiation, and how it may contribute to the effects of PP2/ATRA co-treatment that result in 
differentiation enhancement.  
5.3 Materials and Methods 
Cell culture. HL-60 and NB4 cells were grown
 
in 5% serum-supplemented RPMI 1640 with 1% 
antibiotic/antimycotic from Invitrogen (Carlsbad, CA) and treated with 1 µM ATRA as 
previously described [12]. PP2 from EMD Chemicals (Gibbstown, NJ) was solubilized in 
dimethyl sulfoxide (DMSO) at 10 mM. Cells were treated with a final concentration of 10 μM 
with a 0.1% concentration of carrier DMSO. Dasatinib from Santa Cruz Biotechnology (Santa 
Cruz, CA) was solubilized in DMSO at 5 mM. Cells were treated with a final concentration of 
300 nM. SFK activity inhibition was confirmed by Western blot. The concentrations of drugs 
were approximately 3-4 fold less than that found to cause overt toxicity in titrations monitoring 
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cell growth with a hemacytometer and trypan blue exclusion. 
Antibodies and reagents. Protein A/G beads used for immunoprecipitation, rabbit anti-Vav1, and 
p-Tyr antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). PureProteome Protein 
G Magnetic Beads were from Millipore (Billerica, MA). Antibodies for GAPDH, p-Erk1/2, 
ERK1/2 (rabbit), pan-SFK416, Lyn, Fgr, Lck, Fyn, Vav1, SLP-76, pY-p55/p85 PI3K, total p85 
PI3K, HRP anti-mouse, and HRP anti-rabbit were from Cell Signaling (Danvers, MA). CD38 
antibody was purchased from BD Pharmingen (San Jose, CA). M-PER Mammalian Protein 
Extraction Reagent lysis buffer was from Pierce (Rockford, IL). Propidium iodide, protease and 
phosphatase inhibitors, and DMSO were purchased from Sigma (St. Louis, MO). 
Construction of CD38+ stable transfectants. CD38 knock-in plasmid construction and 
transfection were performed as previously described [1]. To maintain CD38 high expression in 
stable transfectants, the cells were stained with APC-conjugated anti-CD38 antibody (BD 
Biosciences, San Jose, CA) and sorted based on high expression of CD38 using a fluorescence 
activated cell sorter (FACS) flow cytometer (FACS Aria BD Biosciences). Western blotting 
confirmed CD38 expression.  
Western blot analysis and immunoprecipitation. For immunoprecipitation experiments, cells 
were lysed as previously described [12]. Equal amounts of protein were pre-cleared with either 
Protein A/G beads or PureProteome Protein G Magnetic Beads. The beads were pelleted and 
supernatant was incubated with appropriate antibodies and fresh beads overnight. All incubations 
included protease and phosphatase inhibitors used for lysis with constant rotation at 4
o
C. 
Bead/antibody/protein slurries were then washed and subjected to standard SDS-PAGE analysis 
as previously described [12]. 
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FRET (fluorescence resonance energy transfer). Cells were harvested, fixed, and permeabilized 
as previously described [15]. Cells were resuspended in 200 µl of PBS containing 5 µl of 
primary rabbit anti-SLP-76 or rabbit anti-Vav1 and mouse anti-CD38 antibodies and then stained 
with Alexa-350 and 430-conjugated goat anti-rabbit and goat anti-mouse secondary antibodies, 
respectively, from Invitrogen. The immunocomplexes were analyzed using flow cytometry (LSR 
II, BD Biosciences). The FRET signal was measured as previously described [15]. The Alexa 
350 emission from 325 excitation was measured reflected from a 505 longpass dichroic through 
a 440/40 bandpass filter. Alexa 430 emission from 488 nm excitation (from an argon ion laser) 
was collected through a 505 longpass dichroic and 530/30 bandpass filter. Controls with 
secondary antibody(s) only or secondary(s) plus donor or acceptor primary antibody were 
included. Cells stained with just SLP-76 or Vav1 or CD38 primary antibody and Alexa 350 or 
430 respectively were used for compensation controls for spillover into all fluorescence 
collection channels. Timing gates on the collected fluorescence defined acceptor emission 
synchronized to donor excitation. FRET signals were corrected by subtraction of background 
fluorescence of negative controls with just secondary antibodies and compensation controls.   
Signaling experiments. For signaling experiments with Lyn kinase inhibition cells were cultured 
for 48 hours with 1 µM ATRA, and then washed twice with serum-free RPMI 1640 media. 
Appropriate samples were incubated with 10 µM PP2 for one hour and all samples were 
incubated at 37
o
C with constant rotation. The indicated samples were then treated with 5 µM IB4 
for the time points as shown. For samples with ATRA/PP2 co-administration cells were cultured 
for 48 hours with 1 µM ATRA and 10 µM PP2. Signaling experiments were performed as 
described above for IB4 treatment, but the one hour PP2 pre-incubation was omitted. 
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Statistics. Three independent repeats were conducted in all experiments. Error bars represent the 
standard error. The student’s t-test function in MS Excel was used to analyze the data. 
5.4 Results 
5.4.1 CD38 interacts with the ATRA-regulated proteins Vav1 and SLP-76. We first determined if 
there was interaction between CD38 and SLP-76 or Vav1, and investigated whether or not 
ectopically expressing CD38 in the absence of ATRA affected these interactions.  Therefore we 
could compare effects that were dependent on ATRA treatment versus CD38 expression alone. 
Western blotting for total protein showed that SLP-76, Vav1, and CD38 were all upregulated by 
ATRA, with CD38 expression showing dependence on ATRA treatment (Figure 5.1a). CD38 
overexpression in stable transfectants (CD38+) did not significantly increase Vav1 or SLP-76, 
indicating that upregulated expression of these proteins was dependent on ATRA.  
Immunoprecipitation experiments show that ATRA-induced CD38 was able to complex with 
SLP-76 and Vav1, and CD38+ transfectants showed increased interaction (Figure 5.1b). ATRA 
treatment also increased interaction between Vav1 and SLP-76. Untreated CD38+ cells also 
showed increased Vav1/SLP-76 interaction as well, suggesting that CD38 expression regulates 
binding between these two proteins and facilitates a CD38/SLP-76/Vav1 signaling complex. 
GAPDH was used as a loading control for protein input for the SLP-76 probed membrane.  
5.4.2 FRET corroborates the CD38/SLP-76/Vav1 protein complex. We used FRET to confirm 
the interaction between CD38 and SLP-76 or Vav1. We included an additional myeloid leukemia 
cell line (NB4) which bears the characteristic acute promyelocytic leukemia (APL) t(15,17) 
translocation to show that these interactions are not specific to HL-60 cells [39, 40]. As expected, 
CD38, SLP-76, and Vav1 were ATRA-upregulated as indicated in donor and acceptor channels  
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Figure 5.1 CD38 interacts with SLP-76 and Vav1. A: Western blots (WB) for protein 
expression of SLP-76, Vav1, and CD38 in HL-60 cells after 48 hours of ATRA treatment, or in 
untreated CD38+ transfectants. B: Immunoprecipitation (IP) of either SLP-76 or Vav1 shows 
interaction among CD38/SLP-76/Vav1.The IP:SLP-76/WB:SLP-76 blot shows protein loading 
for CD38/Vav1/SLP-76 interaction (top). The IP:Vav1/WB:Vav1 shows protein loading for 
CD38/Vav1 interaction, and WB for GAPDH shows total protein input for the Vav1/SLP-76 
interaction (bottom IP). 
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Figure 5.2 FRET corroborates the CD38/Vav1/SLP-76 interaction. A: Flow cytometry FRET 
histograms confirm 48 hours of ATRA upregulates CD38 and SLP-76 expression and their 
interaction in HL-60 cells. B: Graph showing means of CD38/SLP-76 FRET emission in HL-60 
cells. C: CD38/SLP-76 FRET interaction in NB4 cells after 48 hours of ATRA treatment. D: 
Flow cytometry FRET histograms confirm ATRA-upregulated CD38 and Vav1 expression and 
interaction in HL-60 cells. E: Graph showing means of CD38/Vav1 FRET emission in HL-60 
cells. F: CD38/Vav1 FRET interaction in NB4 cells after 48 hours of ATRA treatment.  
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(Figures 5.2a&d). FRET signals between CD38 and SLP-76 were observed in HL-60 and NB4 
cells after 48 hours of ATRA treatment (Figures 5.2a,b,c) but not in untreated cells that did not 
express CD38. Likewise we detected interaction between and CD38 and Vav1 in ATRA-treated 
HL-60 and NB4 cells (Figures 5.2d,e,f). 
Together, the results from co-immunoprecipitation and FRET experiments demonstrated that 
ATRA-treated HL-60 and NB4 cells showed interaction among CD38, SLP-76, and Vav1, and 
indicated that CD38 facilitated a SLP-76/Vav1/CD38 complex. These results prompted interest 
in CD38/Vav1/SLP-76 interactions with other signaling molecules that are regulated by both 
ATRA and CD38, specifically the SFK Lyn. 
5.4.3 Lyn interacts with CD38, SLP-76, and Vav1, and kinase inhibition affects CD38-stimulated 
signaling. Lyn is upregulated by ATRA and may modulate induction therapy since siRNA 
against Lyn interferes with differentiation [41].  Lyn also interacts with CD38 to promote 
signaling [3, 33, 34]. Therefore, we investigated if Lyn participated in a potential 
CD38/Vav1/SLP-76 signaling complex. Immunoprecipitation experiments showed that Lyn was 
able to interact with CD38, Vav1, and SLP-76 (Figure 5.3a). ATRA-induced CD38 complexed 
with Lyn, and untreated CD38+ cells showed significantly increased interaction, indicating that 
CD38 alone facilitates binding. ATRA treatment increased interactions between Lyn/SLP-76 and 
Lyn/Vav1, but overexpression of CD38 in untreated cells only modestly increased Lyn/Vav1 
binding. Therefore Lyn/CD38 and, to a lesser extent, Lyn/Vav1 binding is modulated by CD38 
expression level but Lyn/SLP-76 binding is not.   
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Figure 5.3 Lyn binds CD38, SLP-76, and Vav1 and its kinase activity regulates CD38 
signaling. A: Immunoprecipiation shows Lyn interaction with CD38, SLP-76, and Vav1 in HL-
60 cells with and without 48 hours of ATRA treatment, and in untreated CD38+ cells.  The 
IP:Lyn/WB:Lyn blot shows protein loading. B: Western blots for SFK/Lyn kinase activity in 
ATRA-treated HL-60 cells using a pan-Y416 that detects active site phosphorylation in all SKF 
members. Cells were treated with ATRA for 48 hours, incubated with PP2 for one hour, and then 
stimulated by IB4 for the indicated time points. p-ERK blot shows PP2 did not significantly 
affect ERK phosphorylation. Total ERK and GAPDH show protein loading. C: 
Immunoprecipitation of c-Cbl shows tyrosine phosphorylation with indicated treatments in HL-
60 cells. Cells treated with ATRA were cultured for 48 hours, cells treated with PP2 were 
exposed to the inhibitor for one hour, and cells were stimulated by IB4 for the indicated time 
points D: c-Cbl tyrosine phosphorylation in CD38+ transfectants in the absence of ATRA treated 
as indicated with PP2 for one hour and then stimulated with IB4. E: Western blot for phospho-
p55/p85 PI3K in HL-60 cells treated as indicated. F: Western blot for phospho-p55/p85 PI3K in 
CD38+ transfectants treated as indicated. Actin shows protein loading in pY-p55/p85 PI3K blots. 
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Since CD38, SLP-76, and Vav1 also interact with c-Cbl [14, 15], we probed for interaction 
between c-Cbl and Lyn but were unable to detect any significant evidence of association. We 
also immunoprecipitated Fgr, another SFK upregulated by ATRA, but were only able to detect 
very weak binding to SLP-76 and Vav1. Western blotting for additional SFKs expressed in 
myeloid cells (Fyn and Lck) showed negligible protein expression (above data not shown). This 
is consistent with previous reports that show Lyn is the predominant SFK in myeloid leukemia 
cells [35, 42]. Therefore, we focused our attention on the role of Lyn in CD38 signaling, which 
motivated interest in whether the Lyn/SFK inhibitor PP2 could modulate signaling propelled by 
the CD38 m(Ab) agonist IB4. Here, IB4 was used as a tool to stimulate CD38 signaling.  
We first confirmed that PP2 was effective in crippling SFK activity in HL-60 cells treated with 
ATRA for 48 hours. We incubated the indicated samples with PP2 for one hour followed by IB4 
treatment as shown to evaluate if Lyn/SFK activity was enhanced by the CD38 agonist ligand 
IB4, and if PP2 was able to inhibit Lyn signaling in the presence of IB4. We analyzed samples at 
various time points after IB4 treatment by probing Western blot membranes with an antibody 
that detects active site phosphorylation of all SFK members (Y416) (Figure 5.3b). We found that 
PP2 was able to inhibit Lyn/SFK activity after IB4 stimulation in ATRA-treated cells  and that 
IB4 ligation did not increase Lyn/SFK kinase activity, consistent with a previous report [27]. 
Lyn may cooperate with CD38 signaling molecules such as ERK, and ligation of Lyn-associated 
CD38 in T cells is followed by ERK and p85 PI3K phosphorylation [32, 34]. We therefore 
evaluated whether the inhibitor affected transient IB4-induced ERK phosphorylation (Figure 
5.3b). Although PP2 was able to inhibit SFK/Lyn kinase activity, it had no significant effect on 
transient ERK phosphorylation after IB4 stimulation of CD38. We then turned our attention 
toward two alternative CD38 signaling targets, c-Cbl and p85 PI3K. 
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We immunoprecipitated c-Cbl and compared tyrosine phosphorylation status after the indicated 
treatments (Figure 5.3c). c-Cbl became phosphorylated after ATRA, and IB4 further stimulated 
phosphorylation. However, pre-incubation with PP2 for one hour was able to abrogate c-Cbl 
phoshphorylation during all time points, indicating that Lyn activity is necessary for ATRA- and 
IB4-induced c-Cbl phosphorylation. We also evaluated c-Cbl phosphorylation in untreated 
CD38+ cells to investigate if the effects of IB4 and PP2 were dependent on ATRA or CD38 
expression alone (Fig. 5.3d). We found that PP2 was still able to block c-Cbl phosphorylation 
induced by IB4, showing the inhibitor blocked CD38-driven signaling independent of ATRA. It 
is noteworthy that the kinetics of c-Cbl phosphorylation induced by IB4 were different in CD38+ 
transfectants compared to ATRA-treated HL-60 cells, suggesting ATRA may temporally 
regulate modification of c-Cbl.  
We also evaluated the effects of PP2 on p85 PI3K regulatory subunit phosphorylation. In HL-60 
cells ATRA induced phosphorylation of the p85 PI3K subunit after 48 hours (Figure 5.3e).  IB4 
did not result in a significant increase in phosphorylation but this may be because ATRA is 
already stimulating p-p85 PI3K, and additional phosphorylation could not be achieved. Like pY-
c-Cbl, PP2 was able to block ATRA-induced p85 phosphorylation. Phosphorylation of the p55 
isoform was not detectable. In untreated CD38+ cells, IB4 was able to stimulate the 
phosphorylation of the p85 PI3K subunit in the absence of ATRA (Figure 5.3f). We also 
detected an IB4-induced transient phosphorylation of the p55 PI3K isoform that was 
undetectable in HL-60 cells. This indicates that CD38 ectopic expression is able to regulate PI3K 
proteins differently than ATRA-induced CD38 in HL-60 cells. PP2 was able to abrogate 
phosphorylation of both the p55 and p85 subunit proteins, similar to its ability to block PI3K 
activity in HL-60 cells. Together this data suggests that Lyn kinase activity regulates CD38-
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stimulated phosphorylation of two downstream targets, c-Cbl and PI3K, in ATRA-treated HL-60 
cells and CD38+ transfectants. PP2 did not affect CD38-propelled ERK phosphorylation, 
indicating that the signaling cascade that results in p-ERK is independent of Lyn kinase activity. 
5.4.4 Early PP2 treatment co-administered with ATRA protects Lyn kinase activity and permits 
CD38-driven c-Cbl and p85 PI3K phosphorylation. After 48 hours of ATRA, one hour of PP2 
incubation inhibits Lyn activity (Figure 5.3). However, if PP2 treatment occurs concurrently with 
ATRA and cells are then cultured for 48 hours, Lyn kinase activity is protected (Congleton et al., 
in press).  The mechanism by which ATRA protects Lyn kinase activity from inhibition by PP2 
is not known. Since one-hour PP2 incubation with ATRA-treated cells blocks SFK/Lyn kinase 
activity but PP2/ATRA co-treatment for 48 hours protects it, we used this strategy to evaluate if 
preserving Lyn activity would permit CD38 ligand-induced phosphorylation of c-Cbl and p85 
PI3K.  
First we confirmed that 48 hours of co-administered PP2 and ATRA were able to protect Lyn 
activity. We compared Y416 phosphorylation in cells that were co-treated with ATRA and PP2 
simultaneously and then cultured for 48 hours to cells that received only ATRA for 48 hours 
followed by PP2 incubation for one hour (Figure 5.4a). All ATRA-treated samples were treated 
with IB4 for the indicated time points to stimulate CD38. As expected, cells treated with ATRA 
and then later incubated with PP2 showed no Y416 phosphorylation, while cells co-treated with 
ATRA and PP2 for 48 hours permitted SFK/Lyn kinase activity.  
We then evaluated if protecting Lyn activity correlated with the ability of ATRA and IB4 to 
stimulate CD38-driven c-Cbl and p85 PI3K phosphorylation. Confirming the results in Figure 
5.3, one hour of PP2 incubation in ATRA-treated cells blocked p85 PI3K and c-Cbl  
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Figure 5.4 Protecting Lyn kinase activity preserves CD38-stimulated c-Cbl and p85 PI3K 
phosphorylation. A: Western blotting shows Y416 inhibition in HL-60 cells treated with ATRA 
for 48 hours followed by one hour of PP2 incubation, but activation after 48 hours of ATRA/PP2 
co-treatment in culture. GAPDH shows protein loading. B: Western blot for p85 PI3K 
phosphorylation in HL-60 cells. Samples were either untreated (C), treated with ATRA for 48 
hours followed by one hour of incubation with PP2 to inhibit Lyn activity (ATRA+PP2 1h), or 
co-treated with ATRA and PP2 and then cultured for 48 hours (ATRA+PP2 48h) which protects 
Lyn kinase activity. C: c-Cbl phosphorylation in HL-60 cells after the treatments described in B. 
D: Cells were treated with ATRA or a combination of ATRA and dasatinib for 48 hours. c-Cbl 
was immunoprecipitated and membranes were probed for tyrosine phosphorylation (top). 
Western blotting was performed for phosphorylated p85 PI3K (bottom). 
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phosphorylation in IB4-stimulated cells (Figures 5.4b&c). However, 48 hour co-treatment with 
ATRA and PP2 permitted ATRA- and IB4-induced c-Cbl and p85 PI3K phosphorylation.  
Finally we used dasatinib, which unlike PP2 abrogates Lyn activity with ATRA co-
administration (Congleton et al., in press), to evaluate if kinase inhibition blocked ATRA-
induced c-Cbl and p85 PI3K phosphorylation (Figure 5.4d). We found that dasatinib blocked c-
Cbl phosphorylation and significantly decreased p85 PI3K phosphorylation, suggesting that 
ATRA-induced pY-c-Cbl requires Lyn activity and ATRA-upregulated p85 PI3K activity is 
largely dependent on Lyn.  
Therefore, SFK/Lyn kinase activity regulated ATRA-propelled and CD38-stimulated signaling 
that results in phosphorylation of c-Cbl and p85 PI3K. This motivated interest in whether or not 
CD38 associations with other ATRA-induced molecules, specifically SLP-76 and Vav1, were 
affected by intact or lost Lyn kinase activity. 
5.4.5 PP2 inhibition of c-Cbl and p85 PI3K phosphorylation coincides with decreased SLP-
76/CD38/Lyn, Vav1/CD38/Lyn, and p85 PI3K/CD38/Lyn interactions. Since SLP-76 and Vav1 
complex with both CD38 and Lyn, we investigated if those interactions were affected by the loss 
of Lyn activity.  We immunoprecipitated Vav1 in samples that were either incubated with PP2 
for one hour after 48 hours of ATRA treatment or received simultaneous PP2/ATRA treatment 
for 48 hours. All ATRA-treated samples were stimulated by IB4 to elicit CD38 signaling. We 
anticipated that an ATRA-induced effect seminal to protecting Lyn kinase activity from PP2 
inhibition may also be relevant to interactions between CD38 and its related signaling molecules. 
We found that the loss of Lyn activity corresponded with a significant decrease in Vav1/CD38 
and Vav1/Lyn interaction (Figure 5.5a). This suggests that these three molecules constitute part  
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Figure 5.5 Lyn inhibition disrupts interactions among CD38-associated proteins. A: 
Immunoprecipitation of Vav1 shows changes in CD38 and Lyn interaction after treatments as 
indicated in HL-60 cells. The Vav1 blot shows protein loading. B: Immunoprecipitation of SLP-
76 shows changes in CD38 and Lyn interaction after treatments as indicated. The SLP-76 blot 
shows protein loading. C: Immunoprecipitation of p85 PI3K shows changes in CD38 and Lyn 
interaction after treatments as indicated. The p85 PI3K blot shows protein loading. HL-60 cells 
in A, B and C that received ATRA treatment were cultured for 48 hours.  
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of a signaling complex that regulates an ATRA-induced and CD38-stimulated modification of 
p85 PI3K and c-Cbl.  
We also immunoprecipitated SLP-76 and probed for CD38 and Lyn. Similar to Vav1, loss of 
Lyn kinase activity resulted in decreased CD38/SLP-76 interaction (Figure 5.5b). Lyn/SLP-76 
interaction was modestly decreased, yet the effects were not as significant as observed with Vav1 
experiments. These results show that loss of c-Cbl and p85 PI3K phosphorylation, which 
corresponded to the inhibition of SFK/Lyn kinase activity, is associated with decreased 
interaction among Vav1/CD38/Lyn and SLP-76/CD38/Lyn. This suggests that a putative 
signaling complex including CD38, Vav1, SLP-76, and active Lyn regulates CD38-driven 
signaling which characterizes ATRA-induced differentiation. Finally we observed that Lyn 
inhibition decreased p85 PI3K/CD38/Lyn interaction (Figure 5.5c), suggesting that CD38 
facilitates a Lyn kinase-containing complex that is directly responsible for p85 PI3K 
phosphorylation.  
5.5 Discussion  
ATRA therapy is successful in treating t(15,17) positive acute promelyocytic leukemia (APL) 
yet it has shown little efficacy in the treatment of other types of leukemias and cancers. The 
t(15,17) negative HL-60 cell line shows ATRA responsiveness and is used as a model to 
investigate how a non-APL leukemic cell can be induced to differentiate. Therefore, elucidation 
of signaling pathways that may confer ATRA responsiveness could broaden its usefulness in 
other diseases and aid in identifying new therapeutic molecular targets.  
CD38 is a leukocyte enzyme and receptor that drives MAPK signaling and differentiation when 
overexpressed [1]. It has important functions in ATRA induction, since siRNA targeting CD38 
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interferes with differentiation, and a CD38 mutant (CD38 Δ11-20) that is not membrane-
expressed also cripples ATRA effectiveness [12, 13]. Identifying signaling pathways 
orchestrated by CD38 that are involved in myeloid maturation is important in understanding how 
ATRA works. 
 In this report we found that CD38 was able to interact with SLP-76 and Vav1, which regulate 
differentiation. Therefore, signaling pathways modulated by these proteins may also be propelled 
by the CD38 receptor. For example downregulation of Vav1 prevents ATRA-induced 
differentiation, as evidenced by loss of nucleoskeleton remodeling and maturation markers [21-
23]. These reports also show that ATRA induction is characterized by the association of 
Vav1/PI3K and Vav1/SLP-76 in the nucleus and Vav1/c-Cbl in the cytosol. Those complexes 
could modulate signaling cascades that are important for neutrophil differentiation, and may be 
coordinated by CD38. CD38 also associates with c-Cbl and interruption of this interaction by a 
c-Cbl mutation (G306E) results in loss of MAPK signaling and ATRA efficacy [14, 15]. These 
studies report that like CD38, c-Cbl binds Vav1 and SLP-76. This supports our results and 
suggests that membrane-expressed CD38 coordinates a putative cytosolic signaling complex 
involving c-Cbl, Vav1, and SLP-76 which could regulate associations with effectors including 
PI3K. 
We also report the involvement of Lyn in a proposed CD38-coordinated complex including SLP-
76 and Vav1, which is significant because SFK inhibitors appear to regulate ATRA-induced 
differentiation (Congleton et al., in press). This motivated interest in whether or not Lyn kinase 
activity was able to modulate signaling driven by a CD38 agonist, IB4. We evaluated three 
targets of CD38: ERK, c-Cbl, and the p85/p55 PI3K regulatory subunit. Cells were treated with 
ATRA for 48 hours to induce CD38, and then treated with the SFK inhibitor PP2 for one hour 
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followed by IB4. We also used CD38+ transfectants in these experiments to evaluate if there 
were signaling effects that were specific to ATRA or CD38 expression alone. 
Since CD38 and c-Cbl interact and both drive MAPK signaling when overexpressed, it is 
possible that they cooperatively contribute to the persistent ERK phosphorylation that is 
characteristic of ATRA treatment [14, 15, 30, 43]. However it appears that CD38-propelled ERK 
phosphorylation is not mediated by Lyn kinase activity since PP2 failed to affect MAPK 
signaling in ATRA-treated HL-60 cells. In addition, we failed to detect interaction between Lyn 
and c-Cbl, suggesting that CD38 and c-Cbl may cooperate to propel MAPK signaling 
independent of Lyn, or that Lyn/c-Cbl interaction is labile. Alternatively, it is possible that Lyn 
participates in CD38-driven MAPK signaling by serving as a scaffold or by facilitating signaling 
complex assembly. For example PP2/ATRA co-treatment for 48 hours enhances Lyn expression 
along with Lyn/c-Raf and c-Raf/ERK interaction, and c-Raf C terminal domain (CTD) 
phosphorylation. These events may be facilitated by Lyn (Congleton et al., in press [44, 45]). 
Therefore the role of Lyn in CD38-driven MAPK signaling and orchestration may involve the 
potential for Lyn to act as a scaffold, which appears to be separate from kinase activity.  
In contrast, Lyn inhibition completely abrogated ATRA- and CD38-driven c-Cbl and p55/p85 
PI3K phosphorylation, showing that Lyn regulates these events in both ATRA-treated HL-60 
cells and CD38+ transfectants. It is interesting that co-administration of ATRA and PP2 
followed by 48 hours of culture protects Lyn from the effects of PP2. Protecting Lyn kinase 
activity permitted CD38 ligand-induced pY-c-Cbl and pY-p85 PI3K in HL-60 cells. Dasatinib, 
which unlike PP2 inhibits Lyn when co-administered with ATRA, blocked c-Cbl 
phosphorylation and impeded pY-p85 PI3K. Therefore Lyn kinase activity regulates CD38-
stimulated signaling and ATRA-induced phosphorylation events that may be driven by CD38. 
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We also show that the loss of Lyn kinase activity coincided with a loss in interaction among 
CD38/SLP-76/Lyn, CD38/Vav1/Lyn, and CD38/Lyn/p85 PI3K. This suggests that the assembly 
of these CD38-associated complexes, which are likely involved in CD38 effector signaling after 
ATRA treatment, is partially dependent on Lyn kinase activity. It also indicates that CD38 
participates in the assembly of a Lyn kinase-containing complex that may result in the direct 
phosphorylation of p85 PI3K. 
It is interesting that co-treatment with PP2 and ATRA, which significantly enhances 
differentiation, preserves Lyn kinase activity (Congleton et al., in press). The mechanism by 
which ATRA protects Lyn from PP2 inhibition is not known. In contrast dasatinib is able to 
inhibit Lyn in the presence of ATRA and also abrogates c-Cbl tyrosine phosphorylation and 
significantly decreases p85 PI3K subunit activity driven by ATRA. Dasatinib still enhances 
differentiation with ATRA co-treatment, but to a significantly lesser extent than PP2. This 
suggests signaling that characterizes normal ATRA induction in HL-60 cells that is mediated by 
Lyn kinase activity may help drive differentiation and confer the increased effectiveness of PP2 
compared to dasatinib. 
In summary CD38-propelled p85 PI3K and c-Cbl phosphorylation, which is characteristic of 
ATRA-induced differentiation, is mediated by Lyn kinase activity. To our knowledge this is the 
first report that Lyn regulates ATRA- and CD38-transduced signaling in myeloid leukemia cells, 
and elucidates how CD38 partner molecules including SLP-76 and Vav1 may regulate 
differentiation during ATRA or ATRA/PP2 co-treatment. 
 
A special thanks to Dr. Miaoquing Shen for providing the data for the FRET experiments.  
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CHAPTER VI 
SRC INHIBITORS, PP2 AND DASATINIB, INCREASE RETINOIC ACID-INDUCED 
ASSOCIATION OF LYN AND C-RAF (S259) AND ENHANCE MAPK DEPENDENT 
DIFFERENTIATION OF MYELOID LEUKEMIA CELLS 
 
6.1 Abstract 
All-trans-retinoic-acid (ATRA)-induced differentiation of human myeloid leukemia cells is 
characterized by persistent MAPK signaling. Fragmentary data suggests Src family kinase (SFK) 
inhibitors enhance differentiation and thus have potential therapeutic value. The present study 
shows that SFK inhibitors PP2 and dasatinib enhance aspects of MAPK signaling and regulate a 
panel of differentiation markers including CD11b and p47
phox
. HL-60 and NB4 myeloid 
leukemia cells show accelerated ATRA-induced G1/0 arrest/differentiation with inhibitor co-
treatment. We also identified components of a Lyn- and c-Raf-containing MAPK signaling 
complex augmented by the inhibitors. PP2 and dasatinib increased ATRA-induced expression of 
Lyn and c-Raf (total and c-RafpS259) and their interaction. The Lyn-associated serine/threonine 
kinase CK2 also complexed with c-Raf and c-RafpS259, and the KSR1 scaffold protein bound c-
Raf, Lyn, and ERK. c-Raf/ERK association was increased by the inhibitors, which is significant 
since ERK may cause c-Raf C-terminal domain (CTD) phosphorylation in a putative feedback 
mechanism. Consistent with this, inhibitor treatment caused more CTD phosphorylation. Lyn 
knockdown decreased c-Raf CTD and S259 phosphorylation. This is the first evidence 
suggesting SFK inhibitors enhance ATRA-induced differentiation through a possible feedback 
loop involving KSR1-scaffolded c-Raf and ERK complexed with Lyn and CK2.  
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6.2 Introduction  
The Src family of tyrosine kinases (SFKs) are a unique group of enzymes that have diverse 
functions in cell proliferation, survival, differentiation, adhesion, and migration. They play 
important regulatory roles in hematopoiesis, but also contribute to hematopoietic cancers. One 
historically prominent paradigm of SFK action is positive regulation of MAPK signaling and cell 
proliferation, and contribution to cell transformation [reviewed in [1]].  
SFK hyperactivity is commonly associated with acute and chronic myeloid malignancies. The 
proliferative signals resulting from the BCR/ABL fusion tyrosine kinase in chronic myelogenous 
leukemia (CML) are driven by downstream SFKs including Src, Lyn, and Hck [2, 3]. Lyn is the 
predominant active SFK expressed in AML cells [4, 5]. It is often hyperactivated, is associated 
with iminitab resistance in CML, and may mediate the effects of the FLT3/ITD mutation found 
in 30% of AML cases [6-9]. Blocking SFK activity has been effective in slowing leukemic cell 
growth [10]. The inhibitor dasatinib has proven clinically successful in the treatment of CML, 
Philadelphia chromosome-positive acute lymphocytic leukemia (ALL) [11], and iminitab-
resistant leukemias [12-14]. 
SFK activity and expression could also modulate ATRA differentiation induction therapy. 
Miranda et al. recently reported that the SFK inhibitor PP2 potentiated ATRA-induced gene 
expression and enhanced the differentiation marker CD11b in myeloid NB4, HL-60, and primary 
acute promyelocytic leukemia (APL) cells [15]. Kropf et al. recently reported that dasatinib also 
increased ATRA-induced CD11b expression [5]. In contrast, some reports show that SFKs may 
positively regulate ATRA-induced differentiation. Lyn and Fgr are upregulated in HL-60 and 
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NB4 myeloid leukemia cells after ATRA treatment, and both were reported to prevent apoptosis 
during granulocytic differentiation [16, 17].    
SFK inhibitors are capable of positive and negative regulatory effects on MAPK pathway 
components. PP2 enhances Ras-independent Raf-1 activation that is mediated by Raf S621 
phosphorylation [18], suggesting that SFK inhibitors are able to positively regulate Raf activity. 
Dasatinib, however, inhibits MAPK activity in the absence of growth factors (GFs) and 
attenuates signaling in the presence of GFs in CML progenitors [19]. MAPK augmentation may 
have implications for ATRA induction therapy, since retinoic acid results in sustained MAPK 
activity which is characteristic of HL-60 maturation [20-22].  
The ability of SFKs to regulate ATRA-induced differentiation and MAPK signaling is therefore 
not understood. This motivates interest in how SFK inhibitors can affect the extent of ATRA-
induced phenotypic conversion or modulate MAPK regulatory molecules. While ATRA is 
proven to be an effective intervention modality for t(15,17) positive APLs, it has not been 
effective in other leukemia subtypes, making means of improving its action in t(15,17) negative 
cells of therapeutic interest. 
In this report the extent to which SFK inhibitors affect differentiation, myeloid leukemia cell 
phenotypic conversion, and MAPK signaling was characterized in t(15,17) negative HL-60 and 
t(15,17) positive NB4 cells. We specifically analyzed the effects of PP2 and dasatinib on two 
ATRA-regulated SFK members, Fgr and Lyn [16, 23].  While Fgr activation was undetectable in 
HL-60 cells, we found that the inhibitors had different effects on Lyn active site phosphorylation 
and cellular tyrosine phosphorylation in ATRA-treated cells. Both, however, were able to 
enhance the ATRA-induced phenotypic conversion and cell cycle arrest in two cell lines. Both 
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inhibitors also increased expression of Lyn and c-Raf, along with their interaction. 
Phosphorylation of c-Raf at S259 (c-RafpS259) and C-terminal serine residues was increased, as 
well as c-RafpS259 and Lyn association. Lyn knockdown prevented ATRA-induced c-RafpS259 
and CTD phosphorylation. CK2 co-immunoprecipitated with c-RafpS259, possibly modulating 
phosphorylation. ERK, which is also capable of phosphorylating Raf, showed increased 
interaction with c-Raf suggesting a MAPK feedback module consistent with the observed 
increase in C-terminal serine phosphorylation. These activities appear to be associated with the 
KSR1 scaffold protein. Similar results were observed for HL-60 and NB4 cells, indicating that 
combination inhibitor/ATRA therapy may be effective in a variety of myeloid leukemia cell 
types. Our results suggest a previously unreported MAPK-linked mechanism associated with 
accelerated ATRA/SFK inhibitor combination therapy.  
6.3 Materials and Methods 
Cell culture. HL-60 and NB4 cells were grown
 
in RPMI 1640 with 1% antibiotic/antimycotic 
from Invitrogen (Carlsbad, CA) and treated with ATRA as previously described [24]. PP2 and 
PP3 from EMD Chemicals (Gibbstown, NJ) were solubilized in dimethyl sulfoxide (DMSO) at 
10 mM. Cells were treated with a final concentration of 10 μM with a 0.1% concentration of 
carrier DMSO. Dasatinib from Santa Cruz Biotechnology (Santa Cruz, CA) was solubilized in 
DMSO at 5 mM. Cells were treated with a final concentration of 300 nM. SFK activity inhibition 
was confirmed by Western blot. The concentrations of drugs were approximately 3-4 fold less 
than that found to cause overt toxicity in titrations monitoring cell growth with a hemacytometer 
and trypan blue exclusion. 
Antibodies and reagents. Antibodies for cytometric analysis of CD11b and for CK2 Western 
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blotting were from BD Pharmingen (San Jose, CA). Protein A/G beads used for 
immunoprecipitation and p-Tyr antibody were from Santa Cruz Biotechnology. GAPDH, p-
RafS259, p-MEK, p-Erk1/2, ERK1/2 (rabbit), KSR1, c-Raf (rabbit), pan-SFK Y416, Lyn, Fgr, 
HRP anti-mouse, and HRP anti-rabbit were from Cell Signaling (Danvers, MA). p-RafS621, c-
Raf (mouse), and Lipofectamine 2000 CD were from Invitrogen. ERK1/2 (mouse) was from 
AbCam (Cambridge, MA). M-PER Mammalian Protein Extraction Reagent lysis buffer was 
from Pierce (Rockford, IL). Propidium iodide, protease and phosphatase inhibitors, and DMSO 
were purchased from Sigma. 
Flow cytometric phenotypic analysis. Immunostaining for CD11b was performed as previously 
described [20] and fluorescence was detected using a Becton Dickinson LSR II flow cytometer 
(San Jose, CA). Cell cycle analysis was performed as previously described [20].  
Western blot analysis and immunoprecipitation. For immunoprecipitation experiments, cells 
were lysed as previously described [24]. Equal amounts of protein were pre-cleared with Protein 
A/G beads. The beads were pelleted and supernatant was incubated with appropriate antibodies 
and beads overnight. All incubations included protease and phosphatase inhibitors used for lysis 
with constant rotation at 4
o
C. Bead/antibody/protein slurries were then washed and subjected to 
standard SDS-PAGE analysis as previously described [24]. 
Creation of shLyn stable transfectants. Plasmid containing shRNA targeting Lyn (target 
sequence: cgagcggaagaactacatt) was from GeneCopia (Rockville, MD). 50µg of plasmid and 
50µL of Lipofectamine 2000 CD (Invitrogen) were incubated at 25
o
C for 25 minutes in serum-
free RPMI 1640 media. 20x10
6
 HL-60 cells were pelleted by centrifugation and resuspended in 
media containing the Lipofectamine/DNA complexes. The cells were electroporated at 
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300mV/960µFD capacitance and immediately transferred to prewarmed media containing 10% 
FBS. After 24 hours debris was removed by centrifugation and cells were cultured as described. 
Cells expressing shRNA targeting Lyn were isolated by FACS sorting for eGFP. 
Statistics. Statistics were analyzed using Microsoft Excel statistical software. 
6.4 Results 
6.4.1 PP2 and dasatinib accelerate ATRA-induced G1/0 arrest. To determine if PP2 and 
dasatinib affected ATRA-induced growth inhibition, we compared population growth during 
different treatment conditions in HL-60 cells. A DMSO vehicle control and PP3, an inactive 
structural analog of PP2, were included to test for toxicity or non-specific effects. These were 
used separately and in lieu of PP2 and had no significant effect on cell growth alone or in 
combination with ATRA (supplementary data S1a). No differences were detected among 
treatment groups after 24 hours. After 48 hours of culture PP2 alone decreased proliferation, and 
cells treated with a combination of PP2 and ATRA show greater growth inhibition (Figure 6.1a, 
top). Strikingly, PP2/ATRA co-treated cells showed no proliferation after 48 hours. The cells 
appeared to have undergone only one doubling followed by G1/0 arrest, consistent with a G1 cell 
cycle block. Unlike PP2, dasatinib had no significant effect on cell population growth (Figure 
6.1a, bottom).  
Next we measured cell cycle phase distribution in HL-60 and NB4 cells. After 48 and 72 hours 
all ATRA-treated and ATRA plus PP2 or dasatinib co-treated populations showed significantly 
more G1/0 compared to untreated cells or cells treated with dasatinib only (Figure 6.1b). PP2-
treated populations showed a modest G1/0 enrichment in both cell lines at 48 hours. We also  
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Figure 6.1 PP2 and dastinib enhance ATRA-induced growth arrest. A: HL-60 cell counts at 
various time points using a hemacytomter. Trypan blue exclusion staining was used to evaluate 
apoptosis. B: Cell cycle analysis of HL-60 and NB4 cells with flow cytometry (*p=<0.5 
significantly higher than untreated control; #p=<0.5 significantly higher than ATRA treatment 
only; $p=<0.5 significantly lower than ATRA treatment only.)  
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detected a corresponding decrease in S and G2/M phase at 72 hours in all ATRA plus PP2 co-
treated samples. HL-60 cells also showed a significant decrease in G2/M within 48 hours with 
co-treatments, and NB4 cells with ATRA plus PP2. Strikingly, approximately 95% of HL-60 
cells and 85% of NB4 cells that received PP2/ATRA co-treatment were arrested in G1/0 by 48 
hours. Although PP3 or DMSO in combination with ATRA showed slight albeit statistically 
significant G1/0 enrichment in some HL-60 sample sets, these increases were remarkably less 
than PP2 plus ATRA (Figure S1b). Therefore, the effects of PP2 on cell cycle and growth are 
largely attributable to SFK inhibition. Together these results suggest that both inhibitors propel 
ATRA-induced growth arrest, but PP2 appears more effective. Trypan blue exclusion staining 
and cytometric analysis of sub-G1 populations indicated that cells were arrested without 
evidence of apoptosis. 
6.4.2 PP2 and dasatinib modulate expression of ATRA-induced differentiation markers. To 
determine if PP2 or dasatinib could further enhance ATRA-induced phenotypic conversion we 
evaluated the expression of myeloid differentiation markers. The α-integrin receptor CD11b is 
upregulated after ATRA treatment and is considered a traditional marker of myeloid 
differentiation. PP2 and dasatinib increased ATRA-induced CD11b expression in HL-60 cells by 
48 and 72 hours (Figure 6.2a). PP2 showed a more dramatic enhancement and had significant 
effects within 24 hours. This is consistent with previous reports [5, 15]. PP3 also enhanced 
ATRA-induced and CD11b expression at some time points, but only modestly compared to PP2 
(Figure S1c). Interestingly, within 24 hours PP2 alone caused a modest induction of CD11b 
expression (Figure 6.2a), indicating that PP2 could propel at least some differentiation. Dasatinib 
alone had no effect on CD11b expression. The leukocyte antigen and differentiation marker  
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Figure 6.2 SFK inhibitors enhance the expression of differentiation markers. A: HL-60 cells 
were treated as shown and immunostained for CD11b at indicated time points. Gating was set to 
exclude 95% of the negative control (untreated cells). (*p=<0.5 higher than untreated cells; 
#p=<0.5 higher than cells treated with ATRA only.) B: Western blots for p47
phox
 expression in 
HL-60 cells after 48 hours of culture. C: Western blots for p47
phox
 expression in NB4 cells after 
48 hours of culture. GAPDH was used as a loading control for B and C. 
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CD38 was also evaluated but neither PP2 nor dasatinib had any significant effect on expression 
(data not shown).  
Maturing myeloid cells are capable of induced respiratory burst/oxidative metabolism by an 
activated NADPH oxidase complex.  p47
phox
, an NADPH oxidase component, is upregulated 
after ATRA. Within 48 hours of culture, cells treated with ATRA alone show enhanced 
expression of p47
phox
 compared to the untreated control in NB4 and HL-60 cells (Figures 
6.2b&c). PP2 alone modestly upregulated p47
phox
 in HL-60 cells supporting evidence that it may 
induce differentiation. Co-treatment with either of the inhibitors modestly enhanced ATRA-
induced p47
phox
 expression in both cell lines. Together these results indicate that both inhibitors 
enhanced ATRA-induced differentiation markers. 
6.4.3 PP2 and dasatinib enhance ATRA-induced Fgr and Lyn expression, but differentially affect 
Lyn activation. After ATRA treatment HL-60 cells show upregulated expression and tyrosine 
phosphorylation of Fgr and Lyn, while siRNA targeting Fgr or Lyn promotes apoptosis [16]. 
Since these ATRA-regulated SFKs may participate in induced differentiation, we determined the 
effects of the inhibitors by comparing protein expression and active site phosphorylation with 
different treatments.  
Fgr was not detectable in HL-60 cells until they were treated with ATRA, which resulted in clear 
induced expression (Figures 6.3a&b). Co-treatment with ATRA plus either inhibitor enhanced 
Fgr expression (Figure 6.3b). Lyn was also upregulated by ATRA, and expression was further 
enhanced by co-treatment with PP2 or dasatinib. Therefore, ATRA/SFK inhibitor co-treatment 
increased protein expression of ATRA-regulated SFKs. Using a pan-SFK antibody that detects 
active site phosphorylation (Y416) in all family members, we found that activation in 
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Figure 6.3 Inhibitors differentially affect Lyn activity but upregulate total Fgr and Lyn 
expression. A: HL-60 cells were treated as indicated for 48 hours followed by 
immunoprecipitation (IP) or Western Blotting (WB). Lyn and Fgr IP membranes were probed 
using a pan-SFK Y416 antibody that detects tyrosine phosphorylation at the active site for all 
SFK members. Membranes were stripped and reprobed for total Lyn and Fgr protein. B: HL-60 
Western blots for phosphorylated SFK members (Y416) and total protein for Lyn and Fgr. C: 
Total cell lysate was Western blotted for tyrosine phosphorylated proteins using a p-Tyr 
antibody. D: NB4 cell Western blots for active and total Lyn expression.  
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immunoprecipitated Fgr (FgrY412) was undetectable regardless of treatment, indicating its 
kinase function is not involved (Figure 6.3a, top). This suggested that a previous report [16] of 
upregulated Fgr tyrosine phosphorylation after ATRA may be relevant to the C-terminal 
autoinhibitory site.  
Evaluation of immunoprecipitated Lyn showed that PP2 and dasatinib crippled basal Y416 
phosphorylation (LynY397) (Figure 6.3a, bottom). However in ATRA-treated cells, dasatinib 
continued to extinguish Lyn active site phosphorylation while PP2 did not. ATRA apparently 
protected Lyn from PP2 in this regard. Consistent with these results pan-SFK Y416 Western 
blotting showed that PP2 and dasatinib both abolished basal SFK activation, but while dasatinib 
continued to block SFK activity after ATRA treatment PP2 failed to do so (Figure 6.3b). Thus, it 
seems Lyn is the dominant active SFK in HL-60 myeloid leukemia cells consistent with a 
previous report [5]. This suggests that Lyn activity is dispensable for ATRA induction since cells 
co-treated with either inhibitor showed enhanced growth arrest and differentiation marker 
expression.  
p-Tyr Western blotting showed that while PP2 alone decreased cellular tyrosine phosphorylation, 
it enhanced the p-Tyr status of at least two ATRA-modulated proteins in the range of 55-58 KD 
and 80 kD, upregulated the phosphorylation of a protein at approximately 150kD, and inhibited a 
100kD protein (Figure 6.3c). In contrast, dasatinib appeared to extensively block cellular 
tyrosine phosphorylation alone and in combination with ATRA. This supports the argument that 
Lyn expression and activity plays a role in mediating ATRA-induced protein tyrosine 
phosphorylation. 
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Finally, we evaluated the effects of PP2 and dasatinib onY416 phosphorylation and Lyn 
expression in NB4 cells (Figure 6.3d). Like HL-60 cells, we found that PP2 failed to block Y416 
phosphorylation in the presence of ATRA while dasatinib was effective. PP2 alone and with 
ATRA increased total Lyn expression; this increase was enhanced by co-treatment. Dasatinib 
alone did not increase Lyn expression but ATRA and co-treatment did. Therefore, treatment of 
NB4 and HL-60 cells with either inhibitor plus ATRA upregulated Lyn expression, coinciding 
with enhanced differentiation.  
6.4.4 PP2 and dasatinib upregulate ATRA-induced c-Raf phosphorylation without affecting ERK 
or MEK activation. ATRA-induced differentiation is driven by a sustained MAP kinase signal 
such that inhibition of MEK activity blocks ERK and c-Raf activation, preventing differentiation 
[21, 22]. Because SFKs can regulate MAPK signaling we determined the effect of PP2 and 
dasatinib on the Raf/MEK/ERK axis.  
Like ATRA, PP2 alone upregulated c-Raf expression in HL-60 cells, and co-treatment showed 
further enhancement (Figure 6.4a). PP2 did not affect ATRA-induced phosphorylation of ERK 
or MEK or total ERK or MEK expression. We then evaluated the phosphorylation status of c-Raf 
regulatory residues. ATRA induces c-Raf S621 phosphorylation by 48 hours and coincides with 
nuclear migration [25], and ectopic expression of the Raf CR3 domain containing S621 enhances 
ATRA-induced differentiation [26]. PP2 alone and with ATRA increased c-Raf phosphorylation 
at S621 within 48 hours and also upregulated c-RafpS259 phosphorylation (Figure 6.4b). PP2 by 
itself and with ATRA strongly enhanced S259 phosphorylation. To our knowledge this is the 
first report of c-RafpS259 modification after ATRA or SFK inhibitor treatment.  
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Figure 6.4 SFK inhibitors modulate c-Raf but not MEK and ERK. A: HL-60 cells were 
treated as indicated for 48 hours. Western blotting shows phospho- and total ERK and MEK, and 
total c-Raf. B: HL-60 Western blots for phosphorylated c-RafpS259 and S621 after 48 hours of 
culture. C: Western blots for MAPK signaling molecules and their phosphorylation status in HL-
60 cells after 48 hours of treatment as indicated. D: Phosphorylation status of c-Raf in NB4 cells 
after 48 hours of treatment as indicated. GAPDH was used as a loading control for all blots. 
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We then determined if dasatinib had similar effects. Dasatinib alone showed little enhancement 
of c-Raf expression or phosphorylation of c-Raf at S621 and S259 (Figure 6.4c). However, co-
treatment increased expression and phosphorylation at S621, with the most significant increase 
in c-RafpS259. Like PP2 dasatinib did not cause detectable differences in MEK or ERK 
expression or phosphorylation after ATRA. This suggests that PP2 and dasatinib have similar 
effects on the Raf/MEK/ERK axis after ATRA treatment. Consistent with this, experiments with 
NB4 cells showed an increase in c-RafpS259 and c-Raf expression after ATRA or inhibitor 
treatment (Figure 6.4d). c-RafpS259 also increased with ATRA or PP2 (but not dasatinib alone), 
and combination treatment with either inhibitor plus ATRA further enhanced phosphorylation. 
These results focused attention on c-Raf as a downstream target of PP2 and dasatinib. This 
motivated interest in identifying c-Raf and c-RafpS259 partners, particularly if there were 
associations between c-Raf and Lyn or other MAPK signaling regulators.   
6.4.5 PP2 and dasatinib regulate interactions between Lyn/c-Raf and ERK/c-Raf, and c-Raf 
phosphorylation. Since the above results suggest a linkage between Lyn and c-Raf, there was 
interest in exploring associations between c-RafpS259 and Lyn, and also with CK2 and KSR1, 
two Raf regulating kinases [27-30]. We first evaluated if the inhibitors affected MAPK signaling 
molecule associations in HL-60 cells. Lyn and c-Raf immunoprecipitation experiments showed 
that these two molecules complex with each other after ATRA treatment, and that this interaction 
is increased by the addition of either PP2 or dasatinib (Figure 6.5a&b). Immunoprecipitated Fgr 
did not show significant interaction with c-Raf (data not shown).  
 
  
 
113 
 
 
 
 
  
 
114 
 
 
 
 
 
 
Figure 6.5 SFK inhibitors regulate interactions between Lyn and MAPK signaling 
molecules. A: After 48 hours, Lyn was immunoprecipitated from HL-60 samples treated as 
shown. Western blotting shows interaction with partner molecules and Lyn confirms the IP. B: 
After 48 hours, c-Raf was immunoprecipitated from HL-60 samples treated as shown. Western 
blotting shows interaction with partner molecules and c-Raf confirms the IP. Interaction with 
Lyn and Lyn-complexed proteins detected in (A) was confirmed. C: After 48 hours, c-RafpS259 
was immunoprecipitated from HL-60 samples treated as shown. Protein interaction with Lyn, 
CK2, and KSR1 was confirmed. Western blotting for CK2 and KSR1 show total protein 
expression. D: ERK was immunoprecipitated from HL-60 samples after 48 hours, and 
membranes were probed to confirm interaction with c-Raf and KSR1, suggesting a KSR1 
scaffolded ERK-mediated feedback loop. E: HL-60 cell Western blot for c-Raf CTD 
phosphorylation of either S289, S296, or S301. F: Immunoprecipitation experiments with NB4 
cells confirm increased interaction with Lyn/c-Raf, Lyn/c-RafpS259, c-Raf/ERK, and potential 
KSR1 scaffolding. Western blotting confirms increases in CTD phosphorylation with 
ATRA/inhibitor co-treatment. 
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The serine/threonine (S/T) kinase, casein kinase II (CK2), is known to complex with and be 
phosphorylated by Lyn and Fgr [31, 32]. CK2 also interacts with KSR1, a scaffold protein that 
modulates MAPK signaling [[30] and reviewed in [33]]. CK2/KSR1 binding facilitates Raf 
phosphorylation, which is dependent on SFK-mediated Raf Y341 phosphorylation [28]. 
Therefore, Lyn may be linked to MAPK signaling and c-Raf binding through interactions with 
CK2 and KSR1. We immunoprecipitated Lyn and c-Raf and found that CK2 and KSR1 complex 
with c-Raf and Lyn (Figure 6.5a&b). We also detected ERK binding to Lyn and c-Raf, which is 
also reported to interact with KSR1 [30, 34]. These results raised the possibility that Lyn/c-Raf 
binding may facilitate a CK2/c-Raf complex that takes place on a KSR1 scaffold, which may 
include ERK. MEK also precipitated with c-Raf and Lyn in ATRA-treated cells but the amount 
of interaction was unaffected by the inhibitors (data not shown). 
Since CK2 is an S/T kinase and we observed a significant increase in c-Raf phosphorylation at 
S259, we precipitated c-RafpS259 and probed for Lyn, CK2, and KSR1 (Figure 6.5c). Co-
treatment with either inhibitor plus ATRA increased interaction between c-RafpS259 and Lyn. 
We were also able to detect CK2 and KSR1 interaction with pRaf259, consistent with these 
proteins existing in a KSR1-scaffolded complex. Total protein expression of CK2 and KSR1 did 
not change after inhibitor co-treatment (Figure 6.5c).  
KSR1/ERK interactions can control MAPK signaling specificity and duration, as well as cell 
proliferation [30, 35, 36]. We found that the inhibitors caused a notable enhancement in ERK 
interaction with c-Raf in ATRA-treated cells (Figure 6.5d). We also observed KSR1/ERK 
interaction. Although reciprocal experiments with immunoprecipitated c-Raf did not show such a 
pronounced increase in ERK interaction, this could be attributed to differences in protein 
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abundance and different proportions of c-Raf or ERK protein that are heterodimerized with each 
other. 
ERK participates in Raf feedback phosphorylation of serine residues in the C-terminal domain 
(CTD), which include S289, S296, and S301 [37, 38]. Therefore we investigated CTD 
phosphorylation status. We found that PP2 or dasatinib alone increased p-CTD, which was 
enhanced by ATRA and further increased by co-treatment (Figure 6.5e). 
Immunoprecipitation experiments with NB4 cells were consistent with these results (Figure 
6.5f). c-Raf and c-RafpS259 showed increased interaction with Lyn after ATRA/inhibitor co-
treatment within the context of a potential KSR1 scaffold. Co-treatment also increased 
interaction between ERK and c-Raf. Finally, p-CTD was increased by ATRA combined with 
PP2 and to a lesser extent dasatinib, although these increases were not as striking compared to 
HL-60 cells. Together, these results suggest that the inhibitor-induced increase in c-Raf and Lyn 
expression facilitates an increase in their interaction, which is accompanied by CK2 and KSR1 
binding. This may be consistent with CK2 kinase activity toward c-Raf that results in c-
RafpS259 phosphorylation, and the ability of KSR1 to act as a scaffold. PP2 and dasatinib 
enhanced ERK association with c-Raf which is consistent with ERK feedback phosphorylation 
within the CTD, also in the context of the KSR1 scaffold. 
6.4.6 Lyn knockdown decreases c-RafpS259 and CTD phosphorylation. To evaluate whether 
downregulating Lyn expression would interfere with ATRA-induced c-Raf phosphorylation, we 
created a stably transfected cell line expressing shRNA targeted against Lyn (shLyn). Lyn 
expression in untreated shLyn cells was similar to wild-type HL-60 cells, but ATRA could no 
longer upregulate Lyn (Figure 6.6a). After ATRA treatment, transfectants were still capable of  
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Figure 6.6 Lyn knockdown decreases c-Raf phosphorylation. A: HL-60 cells and shLyn 
stable transfectants were incubated with ATRA for 48 hours followed by Western blotting for 
total Lyn expression. B: Western blotting for c-Raf CTD serine phosphorylation, c-RafpS259, 
and total c-Raf after 48 hours of culture with or without ATRA. GAPDH was used as a loading 
control. 
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c-Raf upregulation but showed decreased phosphorylation of c-RafS259 and CTD serine 
residues (Figure 6.6b). Therefore, blocking ATRA-induced Lyn upregulation interfered with c-
RafpS259 and p-CTD that is characteristic of HL-60 myeloid differentiation. These results 
suggest that the ATRA-induced increases in Lyn expression modulates MAPK signaling through 
c-Raf.  
We evaluated if Lyn knockdown affected G1/0 arrest or CD11b expression, but there were no 
significant differences between HL-60 cells and shLyn transfectants. This is likely a result of 
achieving only partial Lyn knockdown. As seen in Figure 6.6a, we were only able to decrease 
ATRA-inducible Lyn expression. It is possible that there was still enough Lyn protein in shLyn 
cells to permit cell cycle arrest and CD11b upregulation. The effects we did observe in the 
transfectants that were specific to c-Raf are likely most evident because Lyn has a specific role in 
increased phosphorylation of S259 and CTD residues. 
6.5 Discussion  
ATRA has been successfully used to treat APL for many years. However, patients can develop 
resistance to treatment, and those presenting t(15,17) negative AML have not been responsive to 
ATRA therapy alone. Therefore alternative or combination therapies could improve prognosis 
and survival.  
We found that co-treating t(15,17) negative HL-60 or t(15,17) positive NB4 cells with ATRA 
plus either dasatinib or PP2 (SFK inhibitors) caused significant G1/0 DNA enrichment within 48 
hours compared to ATRA alone. The inhibitor-induced cell cycle arrest led to an investigation of 
differentiation marker effects. Both dasatinib and PP2 enhanced the ATRA-induced upregulation 
of the α-integrin receptor CD11b and NADPH oxidase protein p47phox. PP2 by itself also 
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appeared able to induce some cell differentiation. These results show that SFK inhibitors 
increase cell cycle arrest and differentiation markers in ATRA-treated cells that are either 
t(15,17) positive or negative, suggesting that combination therapy may improve ATRA 
effectiveness in different types of leukemia.  
We then investigated the effects of the inhibitors on Lyn and Fgr, which are upregulated and 
tyrosine phosphorylated after ATRA treatment [16, 23] and therefore may regulate 
differentiation. ATRA increased Lyn and Fgr expression in HL-60 cells, and co-treatment with 
either inhibitor plus ATRA further enhanced expression. NB4 cells also showed Lyn 
upregulation. Fgr active site phosphorylation was not detectable in any samples, suggesting that 
the previously reported increase in phosphorylation after ATRA [16] may be specific to the 
inhibitory C terminal region. Since Fgr activity seemed irrelevant to induced differentiation, we 
turned our attention toward Lyn. 
Dasatinib inhibited Lyn phosphorylation alone and after ATRA treatment in HL-60 and NB4 
cells, but while PP2 alone was inhibitory ATRA treatment protected Lyn activity in co-treated 
cells. It is noteworthy that Lyn is the dominant active SFK in HL-60 and NB4 myeloid leukemia 
cells [5], yet the failure of PP2 to inhibit Lyn after ATRA still coincided with accelerated G1/0 
arrest and phenotypic conversion. The mechanism by which ATRA protects Lyn from inhibition 
remains unknown. Together, these results suggest that SFK kinase activity is not necessary for 
differentiation. One could speculate that SKFs such as Lyn provide scaffolding functions similar 
to ERK, which can act as a scaffold independent of its kinase activity [39]. 
ATRA induction is characterized by MAPK activation, and inhibitors of MEK and c-Raf block 
differentiation [21, 22]. Neither PP2 nor dasatinib affected ATRA-induced ERK or MEK 
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phosphorylation. However both inhibitors further enhanced ATRA-upregulated c-Raf expression 
in both cell lines. The increase in c-Raf is significant, since expression of activated c-Raf drives 
ATRA-induced differentiation [26]. Dasatinib and PP2 also enhanced ATRA-induced c-Raf 
phosphorylation at S621, which is associated with differentiation [25]. Most strikingly, co-
treatment with ATRA alone and ATRA plus either inhibitor increased c-RafpS259 
phosphorylation in NB4 and HL-60 cells,  implicating a previously unreported role for c-
RafpS259 in ATRA-induced differentiation.  
Dual phosphorylation of c-Raf S621 and S259 is characteristic of quiescent cells and associated 
with 14-3-3 binding which can inactivate Raf [38, 40, 41]. Cells expressed mutated c-
RafpS259A show increased proliferation [38], which supports the argument that Raf S259 
phosphorylation may attenuate mitogenic signaling. Although we did not observe any significant 
interruptions in ERK and MEK activation, MAPK signaling depends on the finely-tuned 
orchestration of interactions with scaffolds, regulator molecules, and positive and negative 
feedback loops that include direct regulators such as MEK and ERK. This motivated interest in 
whether there was interaction between c-RafpS259, SFKs, and other MAPK signaling proteins. 
KSR1 is a scaffolding molecule that modulates interactions between Raf, MEK, and ERK, and 
fine-tunes the specificity of MAPK signaling [30]. It also interacts with casein kinase II (CK2), 
an S/T kinase known to complex with and be phosphorylated by Lyn and Fgr [32]. CK2 
phosphorylates KSR1 and is part of the scaffolding complex that regulates MAPK signaling. 
Specifically, c-Raf Y341 is phosphorylated by SFKs; a modification that is reported to be a 
prerequisite for CK2 c-Raf S338 phosphorylation and is dependent on KSR1 scaffolding [28]. 
Our results showed that Lyn was able to complex with CK2 and KSR1, providing a link to 
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MAPK signaling proteins. Consistent with this, ATRA plus inhibitor treatment increased 
interaction between c-Raf and Lyn in HL-60 and NB4 cells. c-Raf also co-immunoprecipitated 
CK2 and KSR1 in HL-60 cells, suggesting a Lyn-containing CK2/MAPK complex scaffolded by 
KSR1. A potential KSR1 scaffolding function was also detected in NB4 cells. c-RafpS259 also 
showed increased interaction with Lyn, CK2, and KSR1. One could speculate that c-Raf 
phosphorylation at S259 is a result of CK2 kinase activity facilitated by Lyn interaction.  
Alternatively, c-Raf/Lyn binding could localize CK2 to one of its targets, many of which include 
key cell cycle regulators [reviewed in [42]].  
Consistent with a MAPK feedback mechanism, we found that after PP2 or dasatinib/ATRA co-
treatment ERK showed more interaction with c-Raf, and also bound KSR1. This coincided with 
upregulated serine phosphorylation at the C terminus of c-Raf. ERK can directly mediate 
feedback phosphorylation of c-Raf on S287, S296, and S301, which controls Raf activation and 
modulates signaling [37, 38]. Thus co-treatment could be attenuating proliferative MAPK 
signaling through a KSR1 scaffolding complex containing a Lyn/CK2/c-Raf/ERK module. 
Knockdown of Lyn by shRNA decreased ATRA-induced c-RafpS259 and CTD phosphorylation, 
suggesting that Lyn regulates c-Raf post-translational modifications. Therefore it is possible that 
alterations in c-Raf phosphorylation status and interactions facilitated by ATRA and Lyn are 
changing the character of the MAPK signaling cascade to regulate induced growth arrest and 
differentiation. Lyn-regulated MAPK orchestration though c-Raf modifications, specifically 
phosphorylation of S259 and the CTD, may reflect differential involvement of feedback loops 
with ERK that significantly slow proliferation and expedite cell cycle arrest and differentiation. 
For example, MAPK stimulation by different growth factors creates positive or negative 
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feedback loops that result in differentiation or proliferation respectively by fine-tuning 
magnitude and longevity [43, 44].  
In conclusion, SFK inhibitors may have the potential to modulate MAPK signaling to enhance 
the therapeutic efficacy of ATRA in the treatment of a variety of myeloid leukemias. Co-
treatment with ATRA plus PP2 or dasatinib may accelerate the phenotypic conversion of AML 
and APL cells to differentiating myeloid cells by targeting specific molecular markers that are 
characteristic of ATRA-induced differentiation. The identification of potential molecular targets 
and mechanisms that may improve the clinical benefit of ATRA encourages further evaluation of 
ATRA/SFK inhibitor combination therapy. 
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Supplementary Data 1. A: HL-60 cells were treated as indicated. Growth and viability were 
measured using a hemacytometer and Trypan Blue exclusion staining. B: HL-60 cells were 
treated as indicated and cell cycle phase was determined by propidium iodide staining and flow 
cytometry (*p=<0.5 significantly higher than untreated control; #p=<0.5 significantly higher 
than samples treated with ATRA only). C: HL-60 cells were treated as shown and 
immunostained for CD11b. Gating was set to exclude 95% of untreated control cells (*p=<0.5 
significantly higher than cells treated with ATRA only at the same time point). 
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CHAPTER VII 
DISCUSSION AND FUTURE DIRECTIONS 
 
All-trans retinoic acid (ATRA) is clinically used to treat t(15,17) positive APL, but its 
effectiveness has been limited to this leukemia subpopulation since it has shown little therapeutic 
success with other types of cancers. Identifying molecules and signaling pathways that confer 
ATRA responsiveness could elucidate mechanisms of action that can be manipulated to expand 
the clinical usefulness of retinoic acid. In addition, the discovery of compounds that enhance the 
effects of ATRA and that could be used in combination therapy may address several of ATRA’s 
current limitations, including resistance, relapse and RAS. In this report we identify several 
signaling molecules and therapeutic compounds that provide insight to ATRA responsiveness 
and may ultimately improve its clinical usefulness. 
The results presented in this dissertation build upon the current knowledge of the role of CD38 in 
cell signaling and its receptor activity, specifically in differentiating myeloid leukemia cells. The 
data also identifies the SFK Lyn as a key regulator of CD38 signaling and ATRA-induced 
differentiation, and suggests that SFK inhibitors may be used clinically to enhance the 
therapeutic benefits of ATRA in a variety of leukemias. We also show ATRA- and 
ATRA/inhibitor modulation of the c-Raf/MEK/ERK axis, which elucidates important 
mechanisms of action involved in leukemic cell differentiation and potential therapeutic targets. 
The leukocyte antigen CD38 is a multifunctional receptor and ectoenzyme that is differentially 
expressed during various stages of lymphocyte and myeloid activation and maturation (reviewed 
in [1]). It is also present in a variety of other cell types and has various implications in disease 
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including CLL, HIV/AIDS, and diabetes. The role of CD38 in leukemia and myeloid 
differentiation is enigmatic. Some reports implicate CD38 in cell proliferation, since interaction 
with an agonist ligand stimulated growth in HL-60, NB4, and patient leukemia cells [2-4]. 
Expression of CD38 in HeLa cells reduces doubling time by shortening S phase [5]. These 
results support a role for CD38 as a pro-proliferative receptor which could explain its 
identification as a negative prognostic marker in CLL. However other studies show that CD38 is 
important for leukemic cell differentiation, since siRNA targeting CD38 cripples the effects of 
ATRA while overexpression drives it [6, 7].  
Since there is evidence for a causal role for CD38 in ATRA-induced differentiation, we 
investigated which domains of CD38 are required. The CD38 enzymatic domain is extracellular 
and metabolizes NAD+ and NAAPD+ to form a variety of products including cADPR or 
NAADP which are calcium mobilizing molecules [8-12]. CD38 catalytic activity depends on the 
E226 residue in the active pocket, and covalent modification with the inhibitors (F-araNAD or F-
araNMN) blocks its function as an enzyme [12-14]. As a receptor, it can propel phosphorylation 
of ERK, c-Cbl, and PI3K, and regulate other signaling pathways such as cytokine secretion [15-
23]. We found that overexpression of CD38 containing a point mutation (E226Q) which blocks 
enzymatic activity was able to propel ATRA induction similar to transfectants overexpressing 
wild-type CD38. In addition, HL-60 cells treated with the specific enzymatic inhibitors F-
araNAD or F-araNMN did not show differences in induced cell cycle arrest and phenotypic 
conversion when compared to cells only treated with ATRA. This indicated that the enzymatic 
activity of CD38 is not necessary for differentiation.  
In contrast, the receptor activity of CD38 that is associated with its membrane expression is 
important for myeloid maturation. We deleted the transmembrane proximal portion of the CD38 
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cytosolic tail (CD38 Δ11-20), which resulted in the loss of CD38 membrane localization. ATRA-
treated CD38 Δ11-20 transfectants showed crippled G1/0 arrest, decreased expression of the α-
integrin receptor CD11b, and virtually no inducible oxidative metabolism, all of which are 
considered traditional differentiation markers. In addition, CD38 Δ11-20 blocked the ATRA-
induced expression of Vav1 and Fgr. These results suggested that the loss of CD38 cell surface 
expression coincided with the loss of its ability to facilitate membrane-associated signaling 
complexes, and that such complexes may include SFKs such as Fgr and the GEF Vav1. It also 
raised the possibility that CD38 Δ11-20 may be sequestering or improperly interacting with 
cytosolic proteins that would normally be membrane-associated, which may contribute to the 
block in differentiation. Future research could investigate how CD38 Δ11-20 is interfering with 
ATRA’s effects by identifying interaction partners that would normally complex with wild-type 
CD38 but are now being modulated by the cytosolic mutant. This could explain in part why 
CD38 Δ11-20 appears to act as a dominant negative since the wild-type, endogenous CD38 
induced in CD38 Δ11-20 transfectants after ATRA treatment was unable to rescue 
differentiation. 
It is noteworthy that CD38 Δ11-20 transfectants were still capable of propelling ERK 
phosphorylation and therefore modulated a component of MAPK signaling. This showed that p-
ERK is not sufficient to drive granulocytic maturation. It is possible that CD38 Δ11-20 is 
changing the character of the MAPK signal to interfere with differentiation. CD38 is capable of 
propelling different types of MAPK signaling and could engage in signal switching. For 
example, CD38 agonist ligand interaction produces a transient p-ERK signal that is typically 
associated with cell growth and proliferation. However CD38 overexpression drives a persistent 
ERK signal that is associated with differentiation. The mutation of CD38 domains that are 
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important for receptor signaling may significantly perturb the regulation of signaling pathways 
such as the MAPK cascade that could have significant cellular outcomes.  
CD38 Δ11-20 cells were also unable to upregulate Vav1 which can modulate the Raf/MEK/ERK 
axis and therefore further perturb MAPK signaling [24, 25]. The literature supporting an integral 
role for Vav1 in ATRA induction is significant, and failure to upregulate Vav1 may also have 
repercussions besides MAPK signaling. For example, Vav1 is thought to regulate PI3K activity 
in ATRA-treated HL-60 and NB4 cells, which results in nucleoskeleton remodeling [26-28]. 
These reports also show increased Vav1 tyrosine phosphorylation and nuclear accumulation after 
ATRA treatment, and that downmodulation of Vav1 by siRNA interferes with changes in nuclear 
morphology that are characteristic of granulocytic maturation. Consistent with this 
overexpression of wild-type Vav1 potentiated the effects of ATRA by accelerating changes in 
nuclear morphology and CD11b expression, which is transcriptionally regulated by Vav1 [26, 
29]. The SFKs Fgr and Lyn are also upregulated after ATRA and may play functional roles in 
granulocytic differentiation [30-32]. Therefore, the inability of CD38 Δ11-20 cells to upregulate 
Vav1 and SFKs combined with the potential for CD38 Δ11-20 protein to interact with other 
signaling molecules may have crippled ATRA responsiveness on several levels.  
We also report the interesting result that while CD38 Δ11-20 cells are incapable of ATRA-
induced granulocytic maturation, they show normal 1,25-dihydroxyvitamin D3 (D3)-induced 
monocytic differentiation. This suggests that wild-type CD38 is not required for maturation 
along the monocytic lineage, or that signaling proteins modulated by ATRA and regulated by 
wild-type CD38 are not important for D3 induction. Further analysis comparing how CD38 
functions in differentiating granulocytic cells versus monocytic cells would elucidate why wild-
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type protein expression is needed for ATRA induction but not D3, and how CD38 Δ11-20 may 
impede the therapeutic benefits of ATRA but not D3. 
The revelation that the receptor functions of CD38 are required for ATRA induction but the 
enzymatic activity is not caused us to focus our studies on the identification of CD38 interaction 
partners and how these molecules are involved in CD38-stimulated signaling. Previous research 
showed that CD38 interacts with the adaptor and E3 ubiquitin ligase c-Cbl [33, 34]. Both 
molecules drive MAPK signaling when overexpressed, and a c-Cbl TKB domain mutant 
(G306E) that does not bind CD38 shows crippled differentiation and fails to drive MAPK 
signaling [35, 36]. This suggests that CD38 and c-Cbl may cooperatively contribute to the 
persistent MAPK signal required for ATRA efficacy, as well as regulate other signaling 
cascades. Previous reports show that c-Cbl binds Vav1, and the adaptor molecule SLP-76 that 
cooperates with c-FMS to propel differentiation [34, 37]. Therefore it was plausible that CD38 
also forms a complex with these c-Cbl-associated proteins. In support of this, the current results 
show that CD38 Δ11-20 transfectants fail to upregulate Vav1 as well as the SFK Fgr. Therefore 
wild-type CD38 signaling may be mediated through SFKs, c-Cbl, Vav1, and SLP-76 in a 
putative signaling complex, and we investigated this possibility.  
Indeed, we detected interaction between CD38, Vav1, SLP-76, and Lyn in ATRA-treated HL-60 
cells and CD38+ transfectants. We did not detect c-Cbl/Lyn interaction indicating that CD38 is 
able to facilitate the assembly of different cytosolic complexes that regulate signaling, or that 
potential c-Cbl/Lyn binding is labile. It is interesting that the c-Cbl G306E mutant that cripples 
MAPK signaling and differentiation fails to bind CD38, but does co-precipitate with Vav1 and 
SLP-76 [34]. Therefore it is plausible that a constitutive cytosolic complex containing c-
Cbl/Vav1/SLP-76 requires CD38-facilitated membrane recruitment through the c-Cbl TKB 
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domain to promote signaling after ATRA treatment. Further research could investigate if the 
TKB mutant also interrupts CD38/Vav1/SLP-76 binding. 
It is noteworthy that untreated CD38+ transfectants showed increased binding between SLP-76 
and Vav1, indicating that CD38 expression alone facilitates complex assembly. CD38 protein in 
untreated transfectants also shows significant interaction with SLP-76, Vav1, and Lyn, again 
demonstrating that expression alone facilitates complex formation without ATRA. However, 
since CD38+ cells do not spontaneously differentiate, it is clear that ATRA-induced or activated 
accessory molecules are required for CD38 to propel differentiation.  
The type and magnitude of CD38 signaling could also change depending on different protein-
protein interactions. Since the CD38 cytosolic domain is so short (20 amino acids) homo- or 
heterodimerization and lateral associations with other membrane proteins could facilitate 
cytosolic platforms for signaling complex assembly. It would be interesting to investigate which 
types of signaling are driven by dimerization, lateral associations on the cell membrane, or 
cytosolic complexes such as the CD38/Vav1/SLP-76/Lyn module identified here. 
We also found that Lyn kinase activity regulates certain aspects of CD38-driven signaling. 
Incubating ATRA-treated cells with the SKF inhibitor PP2 for one hour was able to block CD38-
stimulated tyrosine phosphorylation of p85 PI3K and c-Cbl. However protecting Lyn kinase 
activity by 48 hour co-treatment with PP2 and ATRA preserved pY-p85 PI3K and pY-c-Cbl. 
The inhibitor dasatinib, which blocks Lyn kinase activity in the presence of ATRA, was also able 
to interfere with ATRA-induced c-Cbl and p85 PI3K phosphorylation which may be regulated 
by CD38. Therefore, Lyn activity plays an integral role in these ATRA- and CD38- propelled 
events.  
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Previous reports show that c-Cbl Y731 phosphorylation creates a PI3K docking site and may 
lead to subsequent ubiquitination or sequestration, decreasing cell proliferation [38, 39]. 
Therefore it is possible that CD38 ligand-induced c-Cbl phosphorylation, which is facilitated by 
Lyn, creates an SH2 binding site for p85 PI3K that results in the downregulation of proliferative 
activity. Cbl-b suppression of PI3K activity in leukemia cells enhances chemotherapy-induced 
apoptosis and enhances ERK activation [40]. This could be one mechanism by which CD38 
cooperates with c-Cbl to orchestrate MAPK signaling. In contrast, other reports show that CD38-
mediated growth suppression requires PI3K activity and its association with c-Cbl [17, 18], 
which could require Lyn. A CD38/PI3K signaling axis could also be biphasic and switch 
character depending on a changing cellular landscape in response to ATRA treatment. For 
example, PI3K-induced Akt activation increases within the first 48 hours of ATRA treatment but 
then decreases by 72 hours [41].  
Localization of p85 PI3K may be important as well, since several reports show PI3K activity 
facilitates nucleoskeleton remodeling and is required for ATRA-induced differentiation [27, 41, 
42]. It is possible that c-Cbl sequesters PI3K in the cytosol while an active, unsequestered PI3K 
cooperates with nuclear Vav1 to facilitate structural changes in the nucleus. Future research is 
required to elucidate how the interaction, localization and post-translational modification of c-
Cbl and p85 PI3K may regulate the effects of ATRA. 
These studies also revealed that inhibition of Lyn activity decreases interactions between 
Vav1/CD38/Lyn, and SLP-76/CD38/Lyn. This suggests that phosphorylation events downstream 
of CD38 such as pY-c-Cbl and pY-p85 PI3K are propelled by a putative CD38/Vav1/SLP-
76/Lyn signaling module. As described previously, Vav1 appears important for several GEF-
independent aspects of induced differentiation. Therefore, it is plausible that Vav1 serves as an 
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adaptor or scaffold to facilitate or stabilize protein-protein interactions. For example, Vav1 was 
recently reported to act as a scaffold that stabilizes SLP-76 signaling microclusters [43]. 
We also detected a decrease in CD38/p85 PI3K interaction when Lyn was inhibited, and 
virtually no Lyn/p85 PI3K interaction. This suggested that Lyn kinase activity is required for its 
interaction with p85 PI3K and indicates a direct role in p85 regulatory subunit phosphorylation, 
consistent with the ability of SFKs to activate p85 PI3K (reviewed in [44]). 
It is interesting that we did not detect any changes in CD38-stimulated ERK phosphorylation 
with Lyn inhibition, showing that CD38 differentially regulates signaling. This is consistent with 
CD38’s ability to drive diverse cellular outcomes such as proliferation or differentiation. It is 
likely that different CD38-propelled signals are fine-tuned or switched by interactions with 
upstream and downstream regulators, scaffolds, and feedback loops. This is similar to MAPK 
signal orchestration which is dynamic and involves direct and indirect effectors that require 
scaffolding and feedback loops for fine-tuning and signal-switching (reviewed in [45]). An 
example of this was evidenced in the results described here using SFK inhibitors with ATRA co-
treatment, where we detected a possible positive feedback mechanism involving c-Raf 
phosphorylation that enhanced differentiation.  
In these studies, our discovery that Lyn regulates CD38 receptor signaling led us to further 
investigate the phenotypic effects of the SFK inhibitors PP2 and dasatinib on differentiation 
induced by ATRA. We found that co-treatment with PP2 or dasatinib plus ATRA accelerated 
G1/0 arrest and upregulated expression of differentiation markers including CD11b and p47
phox
. 
Strikingly, we observed that ATRA increased c-Raf serine phosphorylation at S259 as well as 
residues in the C-terminal domain, and this effect was significantly enhanced with inhibitor co-
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treatment. To our knowledge this is the first report of this phenomenon. These results suggest a 
role for c-RafpS259 in cell growth arrest, consistent with a study showing that a c-RafS259 
mutation is proliferative and failed to induce PC12 differentiation compared to overexpression of 
activated wild-type c-Raf [46]. Similarly, increased c-Raf CTD phosphorylation is reported to 
enhance PC12 differentiation [47]. 
We also showed that combination treatment using either inhibitor plus ATRA increased the 
associations between Lyn, c-Raf, and c-RafpS259, as well as ERK and c-Raf. We detected 
interaction with the serine/threonine kinase CK2, which regulates various aspects of the cell 
cycle and is phosphorylated by SFKs, as well as binding with KSR1, a MAPK scaffold reported 
to modulate protein interactions to control signal intensity and duration [48-50]. The increase in 
c-Raf CTD phosphorylation suggested a KSR1-scaffolded signaling module that facilitates c-
Raf/ERK interaction and creates a feedback loop where ERK may phosphorylate c-Raf to 
attenuate mitogenic signaling [47, 51].  
We observed an interesting difference between the inhibitory effects of dasatinib and PP2 after 
ATRA treatment. Dasatinib was able to inhibit Lyn activity in the presence of ATRA while PP2 
was not, yet both enhanced differentiation. The mechanism by which ATRA protects Lyn from 
the inhibitory effects of PP2 is unknown. The results indicate that Lyn kinase function is not 
required for differentiation. Therefore Lyn’s role as an adaptor or scaffold seems to be more 
important, and points to its multi-functionality. In addition, it appears that CD38- and ATRA-
driven tyrosine phosphorylation of c-Cbl is not necessary for differentiation. However, the c-Cbl 
TKB mutant crippled differentiation which indicates another function or modification of c-Cbl is 
involved that may be modulated by CD38.  We did detect low-level, residual p85 PI3K 
phosphorylation after dasatinib treatment, which could be sufficient for its function, yet 
  
137 
 
significant downregulation did not seem to interfere with differentiation. Importantly, these 
results show that Lyn is the primary kinase involved in ATRA-induced pY-c-Cbl and pY-p85 
PI3K. It is significant that PP2/ATRA treatment showed a pronounced enhancement in 
differentiation compared to dasatinib/ATRA co-treatment, and suggests that Lyn/CD38-driven 
tyrosine phosphorylation of c-Cbl and p85 PI3K may give PP2 the advantage over dasatinib in 
accelerating differentiation.  
Future research could explore how ATRA protects Lyn activity and may reveal additional 
molecules that participate in augmenting the effects of ATRA and therapeutic targets. The multi-
functionality of Lyn as a kinase and adaptor/scaffold is also of particular interest. PP2/ATRA co-
treatment upregulates total Lyn protein expression which may enhance its ability to facilitate the 
previously described MAPK feedback signaling module. Since Lyn appears to be multifunctional 
CD38 may also be driving differentiation observed after ATRA- or PP2/ATRA co-treatment by 
participating in the proposed MAPK feedback complex. Since CD38 propels sustained MAPK 
signaling associated with differentiation, it may be an upstream regulator of the feedback 
module. Further research using CD38 knockdown or knockout models will provide deeper 
clarity regarding if and how CD38 is involved in the Lyn/c-Raf/ERK MAPK feedback complex. 
It is also of interest to further explore how CD38 and p-ERK cooperate to maintain a labile 
precommitment memory and if the associated, sustained MAPK signal involves the proposed 
KSR1-scaffold feedback complex. 
In summary, the research presented here advances the understanding of how CD38, SFKs such 
as Lyn, and MAPK-associated molecules may drive ATRA induction. We show that CD38 
receptor functions (versus enzymatic activity) are responsible for driving differentiation. 
Receptor signaling appears to involve the assembly of a signaling complex containing SLP-76, 
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Vav1, and Lyn, which mediates ATRA- and CD38-stimulated signaling including 
phosphorylation of p85 PI3K and c-Cbl. These results support a body of data indicating that 
membrane-expressed CD38 interaction with the ATRA-regulated molecules c-Cbl, SLP-76, 
Vav1, p85 PI3K, and Lyn propels different signaling outcomes associated with induced myeloid 
differentiation. These interactions may also regulate the MAPK cascade, including the persistent 
signal that characterizes ATRA treatment and the newly reported MAPK feedback loop 
involving Lyn, c-Raf, and ERK (Figure 7.1). CD38 interaction with Lyn is of particular interest 
since Lyn appears to perform multiple functions associated with ATRA-induced differentiation. 
Lyn can serve as a kinase that is required for ATRA- and CD38-propelled c-Cbl and p85 PI3K 
phosphorylation in addition to adaptor/scaffold functions that may support the maintenance of 
the MAPK feedback loop reported here (Figure 7.2). Since CD38 and Lyn partner to drive 
signaling, it is possible that CD38 is also key regulator of the Lyn/c-Raf/ERK MAPK signaling 
module and may be a target of therapeutic interest.  
We also show that SFK inhibitors can enhance the effects of ATRA, and that the positive MAPK 
feedback mechanism resulting post-translational modifications to c-Raf may be central to 
inhibitor augmentation of ATRA induction. This report has significant implications for the 
clinical use of SFK inhibitors which may compliment ATRA treatment. Ultimately these results 
suggest additional therapeutic options for resistant or relapsed patients and may improve the 
efficacy of ATRA in treating a variety of leukemias, and could expand its therapeutic use in 
other types of cancers. 
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Figure 7.1 CD38/Lyn/MAPK interaction schematic. ATRA-induced CD38 receptor signaling 
may be stimulated by ligands, membrane proteins, or dimer/oligomerization with itself. 
Downstream signaling events propelled by stimulation involve CD38 interaction partners that 
include p85 PI3K, Lyn, Vav1, SLP-76, and c-Cbl. CD38 may regulate MAPK signaling through 
its interaction with Lyn to drive a persistent cellular signal and the proposed Lyn/c-Raf/ERK 
feedback loop. Previous research shows that Vav1 also interacts with c-Raf showing that CD38 
binds at least two MAPK signaling modulators that are also able to complex with c-Raf. 
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Figure 7.2 Lyn participates in different signaling cascades that characterize ATRA-induced 
differentiation. Lyn is a multifunctional protein that regulates signaling propelled by both 
ATRA and CD38. ATRA- and CD38-stimulated signaling (left) results in phosphorylation of c-
Cbl and p85 PI3K and is dependent on Lyn kinase activity regulated by tyrosine phosphorylation 
of residue Y397. After 48 hours of ATRA treatment, inhibiting Lyn by one hour of PP2 
incubation or 48 hours of dasatinib co-administration blocks c-Cbl and p85 PI3K 
phosphorylation and interrupts interaction between CD38/Lyn/Vav1/SLP-76. Lyn also functions 
as an adaptor/scaffold independent of kinase activity (right) and participates in a proposed 
MAPK feedback signaling module that may be regulated by CD38. 48 hours of co-treatment 
with ATRA plus SFK inhibitors that differentially regulate Lyn kinase activity enhances 
interaction between Lyn/c-Raf and c-Raf/ERK. CK2 and MEK 1/2 also participate in this 
complex which appears to be scaffolded by KSR1. Increased phosphorylation of c-Raf S259 and 
the CTD suggests a MAPK feedback module where ERK may phosphorylate c-Raf to attenuate 
mitogenic signaling and propel cell cycle arrest and differentiation. 
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Mechanism-based small molecule probes for labeling CD38 on live cells. Jiang 
H, Congleton J, Liu Q, Merchant P, Malavasi F, Lee HC, Hao Q, Yen A, Lin H. J Am Chem 
Soc. 2009 Feb 11;131(5):1658-9. 
 
Abstract 
CD38 is a type II transmembrane glycoprotein with multiple functions. It acts as an ecto-enzyme 
as well as a receptor. The enzymatic activity catalyzes the formation of two potent Ca
2+
 releasing 
agents: cyclic adenosine diphosphate ribose (cADPR) from nicotinamide adenine dinucleotide 
(NAD) and nicotinic acid adenine dinucleotide phosphate (NAADP) from NAD phosphate 
(NADP). The receptor function of CD38 leads to the phosphorylation of intracellular signaling 
proteins and the up-regulation of cytokine production in immune cells. These two functions of 
CD38 underlie its involvement in various biological processes, such as hormone secretion, 
immune cell differentiation, and immune responses. Clinically, CD38 is used as a negative 
prognosis marker for chronic lymphatic leukemia (CLL). However, a clear molecular 
understanding of CD38's role in physiology and pathology is still lacking. To facilitate the study 
of CD38 at cellular and molecular levels, here we report a mechanism-based method for 
fluorescently labeling CD38 on live cells. This labeling method does not interfere with the 
receptor function of CD38 and the downstream signaling. The labeling method is thus a useful 
tool to study the receptor function of CD38 in live cells. In addition, since the mechanism-based 
labeling also inhibits the enzymatic activity of CD38, it should be useful for dissecting the 
receptor function of CD38 without interference from its enzyme function in complicated 
biological processes. 
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Interferon regulatory factor-1 binds c-Cbl, enhances mitogen activated protein kinase 
signaling and promotes retinoic acid-induced differentiation of HL-60 human myelo-
monoblastic leukemia cells. Shen M, Bunaciu RP, Congleton J, Jensen HA, Sayam LG, Varner 
JD, Yen A. Leuk Lymphoma. 2011 Aug 24. 
 
Abstract 
Abstract All-trans retinoic acid (RA) and interferons (IFNs) have efficacy in treating certain 
leukemias and lymphomas, respectively, motivating interest in their mechanism of action to 
improve therapy. Both RA and IFNs induce interferon regulatory factor-1 (IRF-1). We find that 
in HL-60 myeloblastic leukemia cells which undergo mitogen activated protien kinase (MAPK)-
dependent myeloid differentiation in response to RA, IRF-1 propels differentiation. RA induces 
MAPK-dependent expression of IRF-1. IRF-1 binds c-Cbl, a MAPK related adaptor. Ectopic 
IRF-1 expression causes CD38 expression and activation of the Raf/MEK/ERK axis, and 
enhances RA-induced differentiation by augmenting CD38, CD11b, respiratory burst and G0 
arrest. Ectopic IRF-1 expression also decreases the activity of aldehyde dehydrogenase 1, a stem 
cell marker, and enhances RA-induced ALDH1 down-regulation. Interestingly, expression of 
aryl hydrocarbon receptor (AhR), which is RA-induced and known to down-regulate Oct4 and 
drive RA-induced differentiation, also enhances IRF-1 expression. The data are consistent with a 
model whereby IRF-1 acts downstream of RA and AhR to enhance Raf/MEK/ERK activation 
and propel differentiation. 
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Investigation of the c-Raf interactome and steady-state multiplicity in retinoic acid-induced 
differentiation of HL-60 cells. 
 
Ryan Tasseff, Johanna Congleton†, Andrew Yen† and Jeffrey D. Varner 
School of Chemical and Biomolecular Engineering, †Department of Biomedical Sciences 
Cornell University, Ithaca NY 14853  
 
 
Abstract 
 
Lessons learned in model differentiation systems, such as the lineage uncommitted human 
myeloblastic leukemia cell line HL-60, could inform the analysis of more complex 
differentiation programs. HL-60 undergoes myeloid differentiation and G1/0-arrest following 
persistent MAPK activation, when exposed to All-Trans Retinoic Acid (ATRA). The 
architecture responsible for ATRA-induced persistent MAPK activation, commitment, cell-cycle 
arrest and differentiation, as well as pretreatment memory effects, is poorly understood. In this 
study, we explored the ATRA-inducible cRaf interactome to determine the functional and 
regulatory architecture responsible for persistent MAPK activation in HL-60 cells. We surveyed 
a panel of 19 possible cRaf interaction partners in the presence or absence of ATRA and the cRaf 
inhibitor GW5074. We found five proteins (AKT, CK2, 14-3-3, Src and Vav1) that interacted 
with cRaf under different conditions. Of these five, the interaction between cRaf and Vav1 
demonstrated a constant correlation with ATRA-inducible MAPK activation and aspects of 
functional differentiation. To better understand the role of cRaf in the ATRA-induced 
differentiation program, we constructed a family of mechanistic mathematical models of the 
transcriptional and post-translational events driving persistent ATRA-induced MAPK activation. 
The proposed architecture was consistent with experimental observation. Bifurcation analysis of 
this model family predicted bistability in ppERK levels as a function of ATRA forcing. A 
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functional consequence of this non-linear behavior was the ability to lock the MAPK cascade 
into a self-sustaining activated state, even in the absence of ATRA. These simulations were 
qualitatively validated with ATRA washout experiments. The results provide further details on 
sustained MAPK activation, mechanistic insight for aspects of cellular memory, and proof-of-
concept that a combination of experimental and computational methods is an effective strategy 
for dissecting complex intracellular programs. 
 
 
